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 Abstract 
African institutions that perform health research need to continuously evaluate their 
practices in order to ensure compliance with international standards of good clinical 
practice (GCP). This mixed-methods study, undertaken at one clinical research site in 
Western Kenya, was an evaluation of GCP compliance at the site, research participants’ 
satisfaction with research procedures, and research participants’ comprehension of 
informed consent. The qualitative portion of the study involved audit of the site’s 
compliance with GCP standards. The quantitative portion was an assessment of 
participant satisfaction and informed consent comprehension, undertaken through 
interviews with a sample of 297 participants. Thematic analysis of the qualitative data 
showed that the site’s performance conformed with GCP standards. Descriptive statistical 
analysis of the quantitative data showed that the majority of study participants were 
content with study procedures.  A majority understood those parts of the informed 
consent process related to study duration and purpose but not those parts of the informed 
consent process related to the purpose and benefits of the study. Univariate chi square 
analysis showed no statistically significant differences in the level of satisfaction by age, 
occupation, or level of education, and there were no statistically significant differences in 
the level of informed consent comprehension by duration in the study or staff levels of 
experience. Implications for positive social change include guiding future health research 
capacity-building efforts in Africa toward better compliance with GCP standards and 
development of higher quality of informed consent procedures. 
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Chapter 1: Introduction to the Study  
The African continent is afflicted with a number of infectious diseases, including 
tuberculosis (TB). Of the 22 countries with the highest burden of TB, Kenya ranks 13th 
on the list, according to the TB report of the World Health Organization (WHO, 2009), in 
which an estimated 132,000 new TB cases were reported, with an incidence of 353 cases 
per 100,000 population. TB continues to fuel the HIV epidemic in this region. TB cases 
and deaths in HIV patients also are a growing problem in Kenya. The WHO (2009) 
estimated that there were 15,000 TB deaths for HIV positive individuals in Kenya. The 
incidence of TB in these individuals is estimated at 39 per 100,000 population (WHO, 
2009). These data show that TB is a disease that should be actively fought in Kenya. 
The burden of TB in Kenya continues to raise concerns. Although the WHO 
(2009) estimates include the per capita incidence of TB to be stable or falling in five of 
the six WHO regions in the period between 2003 and 2006, it is not likely that the 
prospects epidemiological targets set for 2015, as stipulated in the Millennium 
Development Goals, will be met. Vaccinations against TB will combat an epidemic such 
as this one. A vaccine could have a significant impact on the burden of TB globally, but it 
would need to be combined with other with TB control efforts (Murray, 2008; WHO, 
2006). 
As part of TB vaccine development, clinical trial field sites in areas that have high 
TB incidence need to be developed. Areas that are highly burdened with TB also usually 
have high poverty rates and little infrastructure (Aeras, 2010). In order to show the 
vaccine’s efficacy and effectiveness, clinical trials with large study samples need to be 
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conducted in places with high TB incidence but with limited infrastructure for clinical 
research (Aeras, 2010). Significant investment is thus required for building capacity that 
will enable the accomplishment of clinical trial objectives (i.e., show vaccine efficacy). 
Capacity Building for the Conduct of TB Vaccine Trials  
Along with partners, Aeras Global TB Vaccine Foundation—a nonprofit 
organization dedicated to the development of new and effective TB vaccines—invests 
millions of dollars to build and maintain infrastructure necessary for the conduct of larger 
phase clinical trials (Aeras, 2010). Since 2005, the identified sites have been developed 
with the following infrastructure:  
 Development or expansion of their physical facilities to meet the demands of 
large-scale TB vaccine trials. This includes building offices, clinics, and full-
service laboratory facilities and providing state-of-the-art laboratory equipment. 
This investment ensures adequate capacity to support Aeras-sponsored clinical 
trials, but also establishes microbiology laboratory facilities that meet the 
requirements of Good Laboratory Practice (GLP).  
 Development and training of a staff corps that is knowledgeable and proficient in 
the execution of their responsibilities while conducting ethical and regulatory 
compliant clinical research. The staff members are provided with the core 
foundation of knowledge and skills in clinical research on topics including Good 
Clinical Practice, GLP, research ethics, epidemiology, biostatistics, infectious 
disease, and other areas related to the conduct of community-based TB vaccine 
research in accordance with international standards. 
  
3
To date, in partnership with various institutions, Aeras Global TB Foundation has 
sponsored the conduct of epidemiological studies in the following areas (Aeras, 2010):  
 Worcester, South Africa: Through collaboration with the South African 
Tuberculosis Vaccine Initiative (SATVI), two large epidemiology studies and one 
large BCG clinical trial sponsored by Aeras have been completed. The adolescent 
cohort study involving the participation of approximately 6,400 adolescents was 
completed but a sub group of 1,200 participants are still being followed.  
 Kisumu, Kenya: Partnering with the Kenya Medical Research Institute/Centers 
for Disease Control and Prevention (KEMRI/CDC), a study targeting to enroll 
5,000 adolescents for assessing the TB incidence in this age group was initiated in 
2008. A similar study is being conducted with 2,500 infants. 
 Iganga, Uganda: Partnering with the Infectious Diseases Institute at Makerere 
University, a study targeting to enroll 2,500 infants for assessing the TB incidence 
in this age group was initiated in 2008.  
The scope of this dissertation was originally conceptualized as a larger quality 
improvement project in all three sites where Aeras Global TB Vaccine Foundation 
conducted epidemiology studies (South Africa, Kenya, and Uganda). The project was to 
include a GCP audit of the sites, process evaluation of site operations, and staff 
observation. A 12 months intervention was also planned to inject best practice research 
methods in the sites. The process evaluations would have occurred pre and 
postinterventions so see the effect of the quality improvement best practices introduced to 
the processes. Due to changes with my affiliation with the organization, the scope of the 
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dissertation is now restricted to a cross sectional study that includes GCP assessment, 
participant satisfaction, and informed consent comprehension of one site and at one point 
in time. Funds for the comprehensive project with all three sites are no longer available. 
The research for this dissertation was only conducted at the Kisumu site in Kenya. 
This site is currently conducting epidemiology studies to characterize the incidence of TB 
in infants and adolescents. The main goals of these studies are as follows: (a) estimate the 
1 year incidence of TB disease and the annual risk of infection with M. tuberculosis in 
the target populations, (b) estimate the prevalence of TB infection and disease in the 
target populations, and (c) estimate the rate of hospitalization and mortality. Hence forth, 
the Kisumu site will be referred to as “the site” throughout the remainder of the 
document. 
Global Investment in Capacity Building for Health 
In 2000, world leaders committed to a collective partnership to reduce (a) extreme 
poverty, (b) hunger, (c) illiteracy, and (d) disease universally (United Nations, 2009). 
They thus pledged to collaborate and infuse in resources to meet the following eight 
Millennium Development Goals ([MDGs] United Nations, 2009): 
1. Eradicate extreme poverty and hunger 
2. Achieve universal primary education 
3. Promote gender equality and empower women 
4. Reduce child mortality 
5. Improve maternal health 
6. Combat HIV/AIDS, malaria, tuberculosis and other diseases 
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7. Ensure environmental sustainability 
8. Develop a global partnership for development 
 Three of those goals are directly related to improving health systems around the world. 
Capacity building in health research in developing countries is a key component of the 
MDGs (United Nations, 2009). Various researchers have shown that countries in the 
developing world are in need of a health research structure in order to meet the goals of 
improving health and achieve better health outcomes (Lansang, 2004).  
In the past couple of decades, funds have been available to the global health 
community for building and strengthening health systems. From 1990 to 2007, 
development assistance increased from U.S.$ 5.59 billion to U.S.$ 27.79 (Global Forum 
for Health Research, 2009). These funds are originating from a variety of funders such as 
international development agencies, global health initiatives, development banks, 
foundations, nongovernmental organizations (NGOs), and other organizations.  
The global health community has recognized that 10% of the world’s health 
research funds are applied to health problems of 90% of the world population (Global 
Forum for Health Research, 2009). This is also known as the 10/90 gap in health 
research. The burden of neglected diseases such as HIV/AIDS, TB, and malaria add to 
impact of the 10/90 gap. In the past 10 years, world leaders have been increasingly 
devoting higher investment of their GDP to health research. For example, in April 2009, 
U.S. President Barack Obama has committed to allocating 3% of the country’s GDP to 
Research and Development ([R&D] Global Forum for Health Research, 2009). A 
significant portion of these funds are allocated to researching neglected diseases such as 
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HIV/AIDS, TB, and malaria. In 2007, $U.S. 2.56 billion were spend on R&D for 
neglected diseases (Moran, 2009). According to Moran (2009), the leading funders were 
the US National Health Institute ($US 1.25 billion), the Bill and Melinda Gates 
Foundation ($US 0.45 billion), and the European Commission ($US 0.12 billion). The 
main recipients were the International AIDS Vaccine Initiative (IAVI), Medicines for 
Malaria Ventures (MMV), the European and Developing Countries Clinical Trial 
Partnership (EDCTP), the International Partnership for Microbicides (IPM), and Aeras 
Global TB Vaccine Foundation. 
Capacity Building that Strengthens Health Systems in Sub-Saharan Africa  
Clinical trials have been emerging throughout the African continent. Most 
activities are concentrated in South Africa, the location of 892 of the 1,627 clinical trials 
ongoing in Africa (Mboya-Okeyo, 2009). Pharmaceutical manufacturing capacity is also 
burgeoning in the continent. Plans are in place for boosting the drug development 
industry in Africa (Mboya-Okeyo, 2009). All these clinical research sites have benefited 
from investments in capacity building for clinical trials sites in Sub-Saharan African. 
Organizations such as the European and Developing Countries Clinical Trials Partnership 
(EDTCP) have increasingly allocated funds for enhancing the ability to conduct clinical 
trials in order to ultimately address the high burden of disease in the area. In 2003, the 
EDTCP was setup by the European Union with € 200 million for a 5 year period in an 
agreement found in Article 169 of the European Commission treaty (Matee, 2009). 
Organizations such as the EDTCP recognize that the health systems in the developing 
world can be strengthened by the implementation of product development programs. The 
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EDTCP’s core mission is the advancement of needed drug and vaccine products through 
clinical trials into Phase II and III, which ultimately will be used by the population for 
enhanced health promotion (Matee, 2009). 
There is evidence that capacity building for particular health programs ultimately 
ends up enhancing health systems in areas where they are most needed (Dongbao, 2008). 
In response to the HIV/AIDS pandemic, funds were dispensed by donors in the global 
health communities, such as the United States President Emergency Plan for AIDS Relief 
(PEPFAR). These programs are responsible for increased training of health care workers 
in the receiving countries (Dongbao, 2008). Capacity building initiatives for health 
research are occurring in Africa, especially in response to the HIV/AIDS pandemic. 
Particularly, initiatives such as the Global Fund to Fight AIDS, TB, and malaria and the 
World Bank Multi-country AIDS Program (MAP) have been able to affect health systems 
and policies in areas where change is critically needed (Biesma et al., 2009).  
Noted Gaps Not Fulfilled by Past and Existing Capacity Building Efforts 
 In recent literature, the lack of an enabling research environment has been noted 
as a hindrance for the growth of health research in the developing world (Biesma et al., 
2009). The other barriers cited were lack of competent institutional leaders, insufficient 
funds for research and salaries, poor career structure and inadequate infrastructure 
(Biesma et al., 2009). Biesma et al. (2009) reported that only 2% of people with doctoral 
degrees had had more than two grants after training, even though doctoral training had 
been completed as many as 15 years earlier. This lack of grants and financing for 
research contributes to the slow growth of health research in Africa. 
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 There have been limited assessments of compliance with international standards 
of clinical research conducted in the developing world, especially in Africa. Insight can 
be gained into problem areas in noncompliance through looking at data from the US Food 
and Drug Administration (FDA) inspections worldwide (Varshavsky & Platonov, 2004). 
According to Varshavsky and Platonov (2004), 80%-85% of deficiencies were in the 
following areas: 
1. Inadequate consent form  
2. Inadequate drug accountability  
3. Protocol violations  
4. Inadequate/incorrect records and  
5. Failure to report adverse drug reactions  
Given the need for an effective vaccine against TB, invalid data or studies due to any of 
the five deficiency categories listed above cannot be afforded. 
Research has been conducted to shed light on the community’s and the 
participants’ role in the clinical trials. In Sub-Saharan Africa, most of the research on 
vaccine trial participation has been conducted in the HIV/AIDS field (Mitchell, 2009). 
Some of this research included qualitative studies that provided an in-depth 
understanding of participants’ perception of study processes related to recruitment and 
retention. In these studies, researchers seem to be mainly concerned with understanding 
the participants and their communities in order to power vaccine trials adequately and to 
show proper statistical significance for the study outcomes (Mitchell, 2009). These 
researchers were more concerned with aspects of research that address an adequate 
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sample size and minimizing loss to follow-up (Mitchell, 2009). A good number of 
qualitative research studies were geared towards investigating the potential participants’ 
“willingness to participate” (Thapinta, 2002). Some researchers delved into the 
participants’ experiences by asking for their perceptions to help understand the social and 
cultural nature of conducting trials in resource limited settings (Stadler, Delaney and 
Mntambo, 2008). In Stadler et al.’s (2008) study, qualitative data were obtained in order 
to understand the experiences of women enrolled in a microbicide feasibility study. The 
participants were interviewed and participated in focus groups. Stadler et al. found that 
the women were empowered by participating in the study even though they lived in a 
culture and society that fears or denies AIDS. This sense of empowerment may have 
come from the knowledge gained in participating in the study. They were able to engage 
in discussions regarding the importance of knowing one’s HIV status and also became 
more aware of health as related to sexuality and reproduction (Stadler et al., 2008). This 
study is an example of asking for research participants’ opinion on their experiences in a 
clinical research study. My research will go further by obtaining the participants’ opinion 
with the aim of improving the quality of the conduct of clinical research. 
Statement of the Problem 
The main reason for conducting health research is to provide the evidence that is 
required for justifying the need for improving health. The global health community 
continuously invests into health programs due to the needs for better health outcomes 
throughout the world. Particularly, developing countries stand to benefit from health 
research as their health issues keep increasing in magnitude. Hanney and Block (2006) 
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affirmed that, by innovating and collaborating, building health systems helps in the 
conduct and use of information to inform policy, improve health, and close the gaps in 
health equity. In other words, health research is critical in order to keep ensuring public 
health and well-being. 
In the past few years, there has been increase in clinical research studies of 
vaccine efficacy being conducted in Sub-Saharan Africa (Matee, 2009). Since this 
research involves human volunteers who need to be protected, it is critical to assess 
whether the research is being conducted according to international ethical standards for 
clinical research such as GCP (ICH, 2010). Still, there have been no studies of this kind. 
In addition, according to the Centers for Disease Control (CDC) and prevention (2010), 
because most of this research is conducted as part of research capacity building efforts, it 
is important to understand the extent to which the experience or understanding of the 
research participants is linked into the quality improvement process.  
 The clinical research site in Kisumu has had investment in terms of capacity 
building. Due to the amount of capacity building activities that have occurred at that is 
site in the past few years; the site is expected to have a decrease in the findings from 
various audits and assessment from 2008 to 2012. Findings are comments and 
observations made by auditors at the time of inspection.  
Purpose and Significance of the Research 
Developing capacity for quality management for vaccine clinical trials will not 
only help in the field of vaccine research, but it is also expected to build infrastructure for 
health. An assessment of the gaps between the current processes and the standards of 
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operation for the clinical trial sites is needed in the region. This study is a process 
evaluation of compliance with international GCP standards at one clinical vaccine site, 
including an assessment of participants’ understanding of, and satisfaction with, 
recruitment, enrollment, informed consent, and other research activities.  
Social Change 
Research is key and essential to improving health. However, in Africa, health 
research as a discipline still lags behind although its population is affected by a 
significant disease burden (Matee, 2009). The continent has potential for addressing 
health issues; however, political, financial, and intellectual support is required in order to 
realize that potential. There have been several efforts in place to improve health research 
capacity in Africa and currently the results of such capacity are visible, although 
unevenly distributed through the regions (Mboya-Okeyo, Ridley, & Nwaka, 2009). The 
Kisumu research site is an example of some of the successful efforts for capacity building 
for health research in Africa. The social change effected by this evaluation study of the 
Kisumu site is in the success stories of high quality research capacity in Africa. With the 
results from this evaluation study, the site will be able to attract more research and, 
thereby, continue to impact public health in that area of the world. 
The social change effected by this research is also related to the participants’ 
opportunity to voice their opinions on the clinical research that has come into their 
community. In the field of health research, community members are asked to participate 
in research studies and provide data that inform science and/or health. In reviewing the 
available body of literature for this evaluation study, it seems that few research studies 
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provide participants with the opportunity to voice an opinion that can enhance the quality 
of the manner in which a research study is conducted. With this study, it is expected that 
giving participants a voice in the process of continuous improvement of the clinical 
research is beneficial in two ways: it should provide a valuable source of data on the 
relative efficacy of the research process, and it should provide an avenue of 
empowerment for the participants, by making them a part of the planning of research 
procedures. The results of this study will inform researchers and study sponsors on the 
role that participants can play in strategizing and planning for studies within their 
communities. As a result of this evaluation study, the inhabitants of the research site can 
know that the research staff is applying ethical standards that ensure that their rights as 
participants are not being abused or their rights are not disregarded. In the future, when 
they are approached to participate in additional research studies, they can agree to 
participate with confidence that the research staff places importance on quality assurance 
so to continuously improve on the effectiveness and efficiency of research processes and 
achieve better research results that will ultimately improve health systems in their area.  
Conceptual Framework 
The conceptual framework of this study draws on the proceed-precede model for 
evaluation of community-based public health programs, developed by Green and Kreuter 
(1999). This model includes the development of a logic model, which shows the key 
factors, concepts, and variables that influence the overall coherence of a program and its 
evaluation. Logic models have been used in the evaluation of clinical trial networks by 
Kagan et al. (2009) to engage stakeholders such as scientists, managers, and community 
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members in the articulation of their experience of the scientific research enterprise, a 
procedure that is being used in this study. As outlined by Kagan et al., this allows for an 
evaluation that is meaningful and useful to the participants, and appropriate for the 
context of interest. Figure 1 presents a conceptual framework for the evaluation of 
clinical site capacity, and the roles played in this process by (a) participants in the clinical 
research, (b) program sponsors and funders, (c) regulations and guidelines, (d) the 
success of the research studies, and (e) the ultimate impact of the research on the region’s 
health systems.  
In addition to Figure 1, which portrays a theoretical framework for the 
examination of participant understanding and satisfaction, I also draw on the health belief 
model, according to which human behavior can be better understood and even predicted 
when personal and social beliefs are understood (Glanz, 2002). In this case, the attitudes 
of participants in clinical trials – towards the research, for example, or towards health and 
sickness - would be expected influence their behavior as study participants. Factors likely 
to influence participants’ attitudes towards the research include participant-study staff 
interaction, usability of the documentation, physical infrastructure, convenience, 
accessibility, financial factors, procedures and tests, and flexibility of timing of 
procedures.  
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Figure 1. Conceptual framework for a clinical trial site evaluation in a developing 
country based on a logic model (Kagan et al., 2009) 
The environment of this study is the Kisumu site of the Aeras infant TB incidence 
cohort study, which has a prospective and observational design (Aeras, 2008). The 
following are specifics on the infant cohort TB study: 
 The study enrolls infants born in the Karemo division of the Nyanza district in 
Western Kenya. The planned study is targeting sample size of 2,900. 
 Infants are enrolled during a period of 1 year and are followed for up to 2 years. 
Enrollment occurs in the villages and during antenatal clinical visits.  
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 Follow-up is conducted at home every 4 months to collect data on signs and TB 
symptoms or history of household contact with TB. Any identified suspected 
cases of TB are referred to the case verification ward where a comprehensive 
work up is performed (tuberculin skin test, early morning gastric washings for TB 
smear and culture, chest X-ray, and HIV test). 
 Data collection includes perusal of source documents such as TB registers, 
medical charts, and in and out-patient surveillance data.  
 Data are collected on personal digital assistants (PDAs) and case report forms 
(CRF) electronically and on paper 
 The incidence rate is calculated “as the number of new cases of TB, diagnosed by 
a clinician and confirmed by one or more positive cultures” (Aeras, 2008, p. 33). 
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Research Questions 
1. To what extent is the research site's performance in areas impacting data integrity 
and protection of participant's rights and safety in line with GCP and with 
international ethical and regulatory standards? 
2. What is the historical trend of quality data including deviations, audit findings, 
and monitoring findings in the past 2 years? 
3. What is the measurable level of participant satisfaction with recruitment, 
enrollment, and follow-up activities? 
4. What is the measurable participants’ level of comprehension of the informed 
consent form? 
Assumptions and Limitations 
This evaluation study was conducted within an ongoing epidemiology study 
which aims to determine the incidence of TB in a particular study area. Since each site is 
unique, it is unlikely that the study results can be generalizable to a similar population in 
other settings. However, the randomization aspects of the sample size calculation provide 
greater confidence in the generalizability of the results within the epidemiology study 
populations. 
For assessment of informed consent comprehension, some study participants 
completed the questionnaire more than a year after they consented to participate in the 
study. It may be difficult for participants to recall some information about the informed 
consent process due to the long lag in time.  
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 The nature of this study is geared towards the site’s capacity to conduct clinical 
research according to local regulations and international standards. The informed consent 
comprehension was meant to be a snapshot of the staff’s ability to impart information so 
the level of understanding by participants can be deemed satisfactory. This assessment 
could only include the respondents’ self-reports of comprehension, as well as their 
perception of the understanding throughout the informed consent process. Nonetheless, 
this snapshot still provides an indication of the site’s staff capacity to properly administer 
informed consent.  
Summary 
In order to properly proceed with clinical trials for TB vaccines in Kenya, it is critical 
to conduct an evaluation of clinical research capacity building effort in that part of the 
world. There have been a limited number of studies inquiring on the quality of clinical 
research conducted in Africa.   In this study, a GCP audit checklist, a trending analysis of 
historical findings of various compliance assessments, evaluation of participants’ 
satisfaction, and the informed consent comprehension are used to evaluate clinical 
research performance in a site in Kisumu, Kenya.  These data are expected to provide the 
basis of a way forward in setting-up infrastructure for research conduct within stringent 
quality guidelines and international regulations.  Social change will be effected by 
showing’s the site’s capacity for alignment with local and international standards while 
research participants are given an opportunity to contribution to the quality improvement 
process. 
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In Chapter 2, the literature review includes an illustration of a gap for researchers 
who have inquired into the point of view of the research studies’ participants as well their 
comprehension of the informed consent process. In Chapter 3, details are provided on the 
study design, the data collection methods, and tools such as the GCP audit checklist, a 
Participant Satisfaction Questionnaire, and Informed Consent Comprehension 
Questionnaire. The details of data analysis methods, the study site, and the population 
and ethical considerations are also presented. Chapter 4 presents data analysis and study 
findings that include an analysis of the study sample demographics, an analysis of the 
results of the GCP checklist scores, a trending analysis comparing current and historical 
observations and findings on compliance, an analysis of the participations satisfaction 
survey data, an analysis of the informed consent comprehension data, and a summary of 
all results. In Chapter 5, the study outcomes are summarized and conclusions as well as 
recommendations are made to reinforce the impact of capacity building for clinical 
research in Africa. 
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Chapter 2: Literature Review 
Capacity for clinical research needs to include the main elements of research 
operations such as human resources, physical infrastructure (laboratories, clinical 
facilities, offices, etc), data management infrastructure, ethics considerations, and quality 
assurance systems. In the literature review that follows, I aimed to find publications and 
documentations focusing on these elements for clinical research globally and then 
specifically to Africa. The review starts with literature on quality management for clinical 
research in general to highlight the critical importance that quality assurance holds in the 
field of clinical research. The review then branches into the area of ethics since clinical 
research involves human volunteers, and ethical considerations should then be at the 
forefront of this field. Since participant satisfaction is at the heart of this evaluation study, 
I found a few articles where the participants’ opinions were sought. The literature review 
concludes with an examination of program evaluation studies such as the one proposed as 
well as evidence of how research can be used to build capacity for health systems. 
For this literature review, the search first covered major commercial data bases: 
PubMed, and Walden University Library Academic Search Complete/Premier.  The 
words searched included: research capacity building, health research in Africa, TB 
vaccine research, TB vaccine development, regulatory guidelines for vaccine research, 
quality assurance in Africa health research, patient satisfaction, research participation 
satisfaction, and informed consent comprehension.  Next, searches were made on 
references of the articles that seemed more pertinent to the topic of the dissertation.  This 
process was repeated a number of times.  The point of saturation was considered to be 
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reached when new articles ceased to emerge.  Many of the selected references were 
published between 2000 and 2010.  Older references were included if they were 
exceptionally relevant to the review. 
Quality Management for Clinical Research Studies 
Quality management is an integral piece of capacity building (Sobngwi, 2001). 
Quality elements in research include a focus on valid protocols, meaningful informed 
consents, appropriate attention to patient safety, and complete and accurate recording of 
results (Lönnroth, 2008). Quality cannot be achieved by testing and oversight alone. 
Routine monitoring on site has been the standard for the sponsor or funding source for a 
product or intervention to assure performance, but has not been enough for large outcome 
trials and has failed to detect noncompliance (Lönnroth, 2008). 
Various international organizations have collaborated to formulate guidelines for the 
ethical conduct of clinical research. Documents such as the World Medical Association 
Declaration of Helsinki, the International Conference on Harmonization (ICH)/GCP, the 
Belmont Report (Ethical Principles and Guidelines for the Protection of Human Subjects 
of Research), and the Nuremberg Code (Directives for Human Experimentation) were 
published to sum up the directives for ethical considerations for clinical research 
(Bohaychuck, 1991). In an effort to harmonize procedures that are used to standardize the 
practice of clinical research globally, the ICH (2010) devised a set of ethical and 
scientific quality standards for “standard for designing, conducting, recording and 
reporting trials that involve the participation of human subjects” (p. 12). These standards 
are commonly known as GCP. The European Union, the United States, and Japan are the 
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main countries in the ICH that devised the standards (ICH, 2010). However, the clinical 
research practices of Australia, the Nordic countries, and the WHO were also considered 
as the GCP standards were compiled. The ICH adopted an “informal consensus” process 
in developing the guidelines (Grimes, 2005). In other words, they gathered industry and 
regulatory experts and agreed on the set of guidelines through scientific consensus 
(Grimes, 2005). Governments around the world then adopted these standards into laws. 
For example, the U.S. Food and Drug Administration (FDA) has incorporated GCP into 
the Code of Federal Regulations. The GCP guidelines emphasize ethics, documentation, 
monitoring, and audits (ICH, 2010). By showing that a study has complied with these 
standards, researchers are able to have assurance that the study data are sound and that all 
rights, safety, and wellbeing of study volunteers were protected throughout the study. The 
intent was also to create standards for the manner in which clinical trial data were 
submitted to the regulatory agencies so the review and feedback can also take a form that 
is understood globally (ICH, 2010). Although the GCP have been criticized for not being 
inclusive nor evidence-based, they are used around the world to show that ethical 
standards are respected and that quality assurance is accounted for. 
Collecting Quality Assurance Data 
The quality of a clinical trial and its ensuing results is dependent on the level of 
adherence to ethical norms during the conduct of the study (Minnies et al. , 2008). In 
planning, designing, conducting, analyzing, and reporting research, scientists are 
obligated to show their commitment to protecting the rights, safety, and welfare of 
research participants (NIH, 2004). In particular, researchers working in the developing 
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world need to pay particular attention to the participants’ interests since the imbalance of 
power between the funding organizations and the community may lead to the appearance 
of impropriety. Traditionally, quality management is targeted to “elements of structure, 
process and outcome” of the research in terms of “supervision, training, peer review, 
recording and reporting” (Tuberculosis Coalition for Technical Assistance- [TCTA], 
2007, p. 19). In this study, the participants’ feedback on the conduct of the study is 
woven into the plans for quality improvement of clinical research. 
A study may be well designed to obtain the intent outcomes. However, if the 
systems that are in place are faulty, the data obtained could be suspect and the study will 
not have any value, regardless of the resources spent in its conduct. Sandman et al. (2006) 
focused on quality assurance with the intent of safeguarding the data obtained from 
clinical trials. Sandman et al. thus approached the issue of quality assurance with 
measurements that are intrinsic to the study and the data collected. Through collaboration 
with 28 clinical trials site performing studies on various TB therapies, a quality assurance 
(QA) program was set-up with specific performance indicators intending to inform the 
program on the progress of the studies against preset goals (Sandman et al., 2006).  
Due to the multisite and multi continent aspect of the consortium in the Sandman 
et al. study, it was important to have harmonized systems and evaluation tools to ensure 
the standardized conduct of the studies. Sandman et al. (2006) thus implemented a QA 
system that was used to collect assessment information at regular intervals that was fed 
into an electronic system in real time. This system allowed for site to site comparison and 
prompt implementation of corrective action (Sandman et al., 2006). The indicators were 
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related to study performance, such as percent eligible participants enrolled, adherence to 
treatment, percent follow-up visits completed, and treatment completion rates (Sandman 
et al., 2006). These indicators provided information on the performance of studies and, 
thereby, allowed for an assessment on the quality of activities as the studies are 
conducted. With this approach to quality assurance, Sandman et al. were able to show the 
value of staying on top of performance assessment in real-time. Sandman et al. set up a 
framework that can be replicated in other consortia so to facilitate the coordination of 
large, multisite, and multi continent clinical trial programs.  
Assessing participants’ satisfaction also allows for an avenue for the community 
participatory involvement in the quality management and improvement of the research. 
The community needs to have a catalytic relationship with researchers to allow the 
community to become agents of change needed to enhance the health and development of 
that community (Doherty, 2000). In reality, participants may take a more active role in 
research than it is perceived. The participant’s active involvement in the research goes 
beyond giving consent and being recipient of the research intervention. Phenomena such 
as the placebo effect and the Hawthorne effect demonstrate that trial participants are not 
merely passive contributors to research study (Bowera, 2004).  
Collecting Data on Study Ethics 
 Ensuring the ethical handling of participants that take part in clinical trials in 
developing countries is essential when research is being designed and/or funded by 
sponsors in the high income countries. It is crucial to ensure that participants have a 
comprehension of the scope of the research study, risks, benefits, and the voluntary 
  
24
aspect of their participation (ICH, 2010). In South Africa, the quality of informed consent 
in a vaccine trial was assessed in order to identify aspects of the study enrollment process 
that can be improved on its quality (Minnies et al. , 2008). In this study, Minnies et al.  
(2008) found that participants’ levels of education were predictive of their levels of 
comprehension. In an international setting, especially in the developing world, research 
study materials such as the informed consent documents need to be culturally appropriate 
in order to promote better comprehension. 
 With the increasing level of activity for clinical research in Sub-Saharan Africa, 
issues related to ethics have been raised in the research community. Oduro, Aborigo, 
Amugsi, Anto, Anyorigiya, Atuguba, et al.  (2008) conducted a study geared towards 
assessing the understanding and retention of information provided to participants during 
the informed consent process in Ghana. The study by Oduro et al was set-up in a manner 
similar to the present evaluation study in terms of nesting an informed consent study in 
the midst of an epidemiology study involving children in preparation for a vaccine trial. 
In the Ghana study, the site was being prepared for a malaria vaccine efficacy study 
(Oduro et al., 2008). It was acknowledged that special care needs to be taken when 
research is being conducted in resource limited settings whose culture is different from 
the culture of the countries to which western researchers are accustomed. Oduro et al. 
also noted that the research (i.e., intervention trials and social science research) had been 
conducted in the same study area which made many participants aware of the notion of 
clinical research. 
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 Research ethics were further explored by Oduro et al. (2008) when they evaluated 
understanding and retention of informed consent information by administering a 
questionnaire to mothers whose children were previously enrolled in the malaria cohort 
study. Questions were focused on evaluating the understanding of the main themes of the 
informed consent form such as introduction to the study, study procedures, risks and 
benefits, confidentiality, and the voluntary nature of participation into the study (Oduro et 
al., 2008). Oduro et al. showed that there was an understanding of the general research 
concept, which was divergent from previous conclusions from similar studies. Oduro et 
al. attributed this appreciation of the concept of research to the level of research activity 
in this geographical area. Oduro et al.also affirmed the importance of using local field 
workers in the enrollment and recruitment procedures. The fieldworkers from the same 
community that are speaking the same language as the participants are able to establish 
an ease in the environment that eases the decision-making process of participating in a 
study. 
 Evaluating the consenting process was also conducted at a research site in Kenya. 
In a qualitative study, Gikonyo, Bejon, Marsh, & Molyneux (2008) examined the effect 
of social relationships between the community members and research on the quality of 
informed consent practices. Gikonyo et al. found that conducting a research study inside 
the community enhances the study participants’ perception of their involvement in the 
study. In other words, the participants have more buy-in into the study and they feel more 
implicated since the study is being conducted in their daily environment. This particular 
assessment was conducted adjunct to a Malaria vaccine trial in Kenya. Gikonyo et al. 
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found that having local fieldworkers recruiting and enrolling in the community allowed 
for a decision-making that is more suitable for a collective society, such as the ones in 
Sub-Saharan Africa. By visiting the homes of potential participants, the field workers 
were able to speak to members of the household/community such as the husbands, 
fathers, mothers, or mothers-in-law (Gikonyo et al., 2008). These nonparticipating 
community members play a role that is critical in the decision-making of study 
participants. Gikonyo et al. also found that long-term studies such as vaccine trials have 
the tendency to incite rumors about the research and researchers in the community. 
Building a trusting relationship with the community helps to alleviate the rumors as they 
emerge and also to provide for an opportunity to clear-up any misconception or 
misunderstanding about the research in the community (Gikonyo et al., 2008). Gikonyo 
et al. suggested that the consent process should not merely consist of one-time 
information giving sessions. Instead, the researchers ought to take a continuous and 
community-encompassing approach to the decision-making of volunteering for a clinical 
research study (Gikonyo et al., 2008). 
In the past few decades, accomplishments have been made in medical ethics in 
regards to the research participant relationship with investigators. Unlike in the past, the 
research participants now are given more autonomy while involved in clinical studies. 
The decision-making process is more shared between the medical and research staff and 
the volunteers (Falagas, Korbila, Giannopoulou, Kondilis, & Peppas, 2009). In keeping 
with the new developments, regulations, and laws that require respect for the participant’s 
autonomy, the issue of adequate informed consent is usually raised. Falagas et al. (2009) 
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examined various clinical trials in order to ascertain the level of understanding in the 
informed consent process for research participants. Falagas et al. based their review on 
the basic elements of informed consent:” voluntarism, capacity, disclosure, understanding 
and decision” (p. 420). One of the findings from the review performed by Falagas et al. 
was related to the lack of understanding of the investigative nature of clinical trials. 
Research participants failed to acknowledge that they were participating in a research 
study for exploratory purposes and not necessarily for therapeutic purposes (Falagas et 
al., 2009). This notion is sometimes called therapeutic misconception. It should then be 
noted that investigators have the burden of not only ensuring comprehension of the aim 
of the study, but they also need to pay particular attention to assisting the participants in 
valuing the research study as an investigation instead of an established therapy or 
treatment.  
Clinical trials involve notions such as randomization, voluntarism, and risks 
versus benefits that may not be easily understood. Falagas et al. (2009) found that 
randomization is only understood by half the participants in most studies. Falagas et al. 
suggested using novel methods of communication information in clinical trial process 
such as video materials. Falagas et al. also recommended that sufficient amount of time 
be given to research participants to ensure that the information imparted is retained in a 
lasting manner.  
Administration of informed consent has been researched. In an effort to obtain 
empirical data on the informed consent process in South Africa, Moodley, Pather, & 
Myer (2005) studied informed consent and participant perception in an influenza vaccine 
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trial. In these trials, the informed consent process also took a community-wide approach 
combined with an individual process in the home. The informed consent assessment 
questionnaire was given 4 to 12 months after enrollment into the vaccine trial. Moodley 
et al. found that the majority of participants were cognizant that the vaccine being tested 
was experimental and they were aware of their freedom to withdraw from the study as 
they wished. However, a number of participants did not understand that their assignment 
to either the vaccine or the placebo group was by chance (Moodley, Pather, & Myer, 
2005). Hence, Moodley et al. concluded that complex consent themes, such as 
randomization and placebo, were not understood in this study (Moodley, Pather, & Myer, 
2005). Even though the informed consent process was extensive and involved, it is still to 
the researchers’ best interest to expand the consenting procedure beyond information-
giving and focus more on relating the consent themes in terms and circumstances best 
understood by research participants. 
 A study was conducted in Australia with aboriginals in order to test various 
designs of informed consent documents as well as the manner in which the information 
was delivered (Russell, Carapetis, Liddle, Edwards, Ruff, & Devitt, 2002). Russell et al. 
(2002) showed that a participatory and communal approach to informed consent was 
more effective than the reading of fact that Australian aboriginals come from a 
community where decisions are made collectively. The informed consent process was 
more effective when the participants were allowed to be informed as a group and 
discussion was encouraged among the participants (Russell et al., 2002). Researchers 
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such as these highlight the need to engage the participants in the process of identifying 
ways to improve the quality of conducting clinical trials. 
Taking into account that cultural differences and traditions may impact 
participants’ comprehension of information imparted during the informed consent 
process, Länsimies-Antikainen, Pietilä, Kiviniemi, Rauramaa & Laitinen (2009) aimed to 
assess comprehension of informed consent in older clinical study volunteers in Finland. 
Lansimies-Antikainen et al. also aimed to determine whether the study participant’s 
appreciation of understanding clinical trial informed promoted his or her long-term 
continued involvement in the study. The participants involved in this study were 
originally included in a randomized controlled intervention trial “on the effects of regular 
physical exercise and diet” (Lansimies-Antikainen et al., 2009, p. 2). A self-administered 
questionnaire was used for data collection in a 23 month period. The questionnaire was 
focused on the following aspects of informed consent: information, understanding, 
competence, voluntariness and decision-making” (Lansimies-Antikainen et al, 2009, p. 
2). Lansimies-Antikainen found that most participants were satisfied with the level of 
understandability of the information with which they were provided. Also, higher levels 
of education as well as being content with personal health were correlated with proper 
understanding of the trial information with which they were provided (Lansimies-
Antikainen et al, 2009). In terms of willingness to continue to participate in clinical trial, 
participants who were satisfied with their own health were more agreeable (Lansimies-
Antikainen et al, 2009). It was noted that particular care needed to be given to the 
informed consent process when participants with lower levels of education were 
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involved. Lansimies-Antikainen et al. (2009) highlighted the need for tailoring the 
informed consent process in various cultures in order to improve comprehension and 
promote the participants’ autonomy in deciding to enroll in a clinical research study. 
Some aspects of research may be difficult to explain to participants in some 
societies in the developing world. For example, it may be challenging to translate 
technical words such as “randomization” or even some concepts such as the importance 
of the voluntary nature of participation in a research study (Bhutta, 2004). In the 
developing world, it may also be difficult to ascertain a participant’s real ability of giving 
voluntary consent if the person’s autonomy in decision making is not clear (Bhutta, 
2004). For example, a woman may be listening to the research staff soliciting enrollment 
into a study, but she may not be able to make the decision without consulting with other 
family members such as her husband or father. Bhutta (2004) has found that there is 
minimal research knowledge published in the area of consenting for research in the 
developing world (2004). Bhutta suggested that additional investigations should be 
conducted to determine “the validity of the process and the relationship of various 
informed consent procedures to outcomes and participants ‘experience of research” (p. 
775). In other words, additional research is needed to evaluate the suitability of the 
informed consent process and how the participants going through it. 
Study Volunteers’ Opinions on Participation 
Lazovski et al. (2009) saw the need to explore benefits and burdens of 
participation in a clinical trial that are beyond the actual clinical, medical, therapeutic or 
research aspects of the trials. This study is another example of inquiring the participant’s 
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point of view in order to inform the discipline of clinical research itself not a disease or 
health outcome. The participants surveyed were taking part in an HIV treatment study in 
25 countries that included Argentina, Brazil and Thailand over a number of years. The 
questionnaire used was translated, back translated, and pretested before being applied in 
the survey study.  
Study participants provide valuable opinions when inquired. In the Lazovski et al. 
study, the respondents identified medical and as well as non-medical benefits. In terms of 
health advantages from participating in a clinical trial, improvement in personal health 
condition was most cited (Lavoski et al., 2009) was most cited. Improved access to health 
care was also cited as a benefit to trial participation. In terms of nonmedical benefits 
cited, improved emotional conditions, time and money saved from the care received in 
the trial, access to quality health information were cited (Lavoski et al., 2009). The 
survey also identified nonmedical burdens such as problems at work for time spent in the 
clinical trial (Lavoski et al., 2009). The points highlighted by these participants show that 
understanding the participants’ need adds to the research. This study provides an insight 
in trial’s participants’ perception in being involved in a clinical trial as related to non-
health and non-medical aspects of the research. It is crucial to understand these other 
reasons in order to encourage trial participation, design studies, and conduct them in a 
manner that best serve the participation without compromising the scientific information 
that is sought. 
A good number of studies soliciting the participants’ point of view have been 
geared towards study participants’ willingness to participate in clinical research. These 
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types of studies educate the research communication how to best find, retain, and 
motivate individuals that may potentially take part in clinical trials. Volkmann, 
Clairborne, & Currier (2009) examined the relationship between patients and their health 
care providers in settings that may involve HIV clinical trials (Volkmann, 2009). They 
inquired into the impact that this relationship would have as a potential trial participant is 
contemplating enrolling a study (Volkmann, 2009).  The participants may be influenced 
by this relationship. 
A self-administered questionnaire was provided to patients frequenting the Center 
for Clinical AIDS Research and Education (CARE) in Los Angeles. The study population 
included patients that had participated in trials in the past as well as those that were still 
enrolled in existing studies. The study by Volkmann et al. (2009) showed that a 
significant majority of these patients would be interested in enrolling additional studies in 
the future. This study also indicated that most patients are more willing to participate in 
clinical trial if they were contacted by their primary care provider (Volkmann, 2009). In 
this study, it was also found that participants were less willing to participate in a trial if 
they were approached by a third party such as an outreach coordinator (Volkmann, 2009). 
This finding may be due to the established relationship of trust that exists between the 
patient and the provider. The authors note that this study may be limited by selection bias 
since respondent were recruited from one university-based clinic and were mostly males 
(Volkmann, 2009).  
In vaccine development, researchers need to be able to design studies that 
promote future optimal uptake of vaccine and they need to understand how the 
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community will affect certain vaccine parameters such as efficacy, dosage and access 
sites (Newman, 2004). Hence, engaging the community and the study participants 
becomes crucial in vaccine research. The community and the participants should be 
viewed as active partners not just in the study design to protect the statistical soundness 
of the data, but also throughout the clinical research study in order to improve on the 
study conduct and compliance with ethical and regulatory standards. The most 
compelling evidence of the necessity of actively engaging the community is illustrated in 
the case of a malaria vaccine trial site in Papua, New Guinea. Reeder & Taime (2003) 
worked with the community for over 25 years and spent a significant amount of time and 
effort in “knowing the community” and involving them as partners and not merely as 
“subjects” (p.281). Vaccine development at this site was greatly enhanced by the 
researchers’ familiarity with the community and the research participants.  
The same type of literature of research in TB vaccine seems to be minimal. In the 
present study, the aim is more focused on allowing the participants’ perspective to 
improve the internal processes for the conduct of a TB research study. Using the 
“patient” perspective to improve on processes is widely used in the general health care 
field. In healthcare, the patient satisfaction is sought to better understand the attributes of 
health care processes that are important to and preferred by patients (Hunter, 2009). For 
the TB field, the Tuberculosis Coalition for Technical Assistance developed a guide that 
uses the patients’ point of view for improving the quality of care in clinical settings for 
TB care. As long these lines, I will request the clinical study participants’ perspective to 
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mold strategies for improving study procedures. This approach will allow for the 
participants to contribute to shaping research and enhancing TB vaccine research. 
The premise of the study is that additional tools and strategies are required to 
further improve quality at clinical research sites overall and with special focus in resource 
limited settings. Based on Aeras’ experience with capacity building and implementation 
of quality management at clinical research sites conducting TB studies, auditing and 
monitoring alone and implementation of basic quality systems has not produced the level 
of quality required as evidenced by serious or numerous errors, repeated deviations or 
quality issues, or gaps in documentation or processes. This need for additional tools and 
strategies for quality improvement at sites is increasingly being put forth in the literature 
and demonstrated in continued findings from regulatory body inspections of poor data 
compliance and quality and ethical violations as mentioned previously (FDA, 2007; 
Varsharvsky, 2004).  
Evaluation of Capacity Building Efforts  
Evaluation of capacity building projects are intended to appraise the progress, 
merit or performance of the initiative in order to inform decision-making for the future or 
just to ascertain a current status of the project. Since there is a significant number of 
health needs with limited resources to address those needs, it is important to maximize 
any capacity building so to make them cost effective and efficient. The benefits of 
capacity building are well documented in the literature. In previous experience, capacity 
building of health systems has been shown to improve health systems and services, 
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expand organizations’ abilities to solve problems as well as enhance the chances for 
maintenance and sustainability (Smith, Coveney, Carter, Jolley, & Laris, 2004).  
Once investments are made to either build or strengthen health systems for 
sustainable outcomes, the expected return is understandably significant. Various methods 
have been used for capacity building projects. For instance, a capacity building project 
for promoting leadership in South Australia was evaluated. The following methods were 
used for the study: telephone surveys, face to face interviews with key informants, focus 
group discussions and document review (Smith et al., 2004). For this project, the 
framework of capacity building was structured around three areas: “project infrastructure 
development, organizational problem solving capabilities and program sustainability” 
(Smith et al., 2004). Indicators for the status of the project were centered on these three 
areas. Smith et al (2004) showed that the project performed and met its capacity building 
goals. This is an example of successful capacity building. 
In this evaluation, Smith et al (2004) chose to ascertain the performance of the 
project through a framework of capacity building so as to discern the value added to 
health systems as whole. A traditional evaluation would have taken the form of 
measuring the project performance against its inherent objectives such as increasing 
consumption of vegetable in a certain time period. However, Smith et al. (2004) chose to 
analyze the project outcomes in terms of the additional value that they bring to the health 
systems as a whole in the study area.  The evaluation was useful. 
Further studies have been conducted in regards to capacity building for health 
research.  Le Thi Thu et al. (2008) opted to conduct a capacity project for improving 
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health outcomes by running a 5 day educational programs for community leaders in the 
Kim Son district of the Ninh province in Vietnam. Le Thi Thu et al. (2008) aim was to 
educate community leaders such as political leaders, teachers, women’s group organizers 
and others. These leaders were expected to use their influential positions in the 
community in order to inspire the community at large to adopt living ideals that are 
beneficial to health.  
Le Thi Thu et al’s study took place in eight communes that were randomly 
selected from 14 eligible communes. The chosen communities were then randomly 
separated into an intervention group and a control group. In the end, 304 community 
leaders participated with 150 in the intervention and 154 in the control group (Le Thi Thu 
et al., 2008). These study participants were part of a 5 day education course with the 
objectives of “knowledge and skills regarding a healthy living environment, to 
understand potential health risks of unsanitary conditions, to provide counseling and 
promote a healthy living environment and apply effective health communications” (Le 
Thi Thu et al., 2008, p.360). The effectiveness of the educational program was evaluated 
with pre and posttests. Statistical analysis such as t-test, χ2, analysis of variance and linear 
regression analysis were used. The 5 day educational program was successful in 
enhancing the community leaders’ knowledge and skills as related to identified healthy 
living objectives (Le Thi Thu et al., 2008). This is another example of successful capacity 
building. 
Although the educational intervention intended to improve the community’s 
health, it would have been interesting to evaluate the impact of the educational program 
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within the community itself in terms of health outcomes. For example, the evaluation 
could have included testing the community members that were reached by the leaders 
that participated in the 5 day course. Or, the pre and post tests could have included 
random members of the community that are influenced by the leaders that participated in 
the program. The study could have been affected by the potential of contamination of one 
community from another depending on the geographical distance that separates the 
intervention communities from the control ones. 
Process evaluation is necessary in order to better refine and troubleshoot the 
implementation of the health program. Assessing a program when it is active allows for 
an opportunity to identify problems, actual or potential, in order to better address them. In 
research systems, a process evaluation also gives an opportunity to determine if the 
research program is being conducted as it is intended or if the intended results are being 
collected. Tumiel-Berhalter, Mclaughlin-Diaz, Vena & Crespo (2007) performed process 
evaluation of a community based participatory research program that aimed to build 
capacity for research in a community in Buffalo, New York. The program’s aim was to 
develop community outreach workers skills through training and education. The trained 
outreach workers were then able to educate the community at large and collect data for 
Asthma research. Tumiel-Berhalter et al (2007) presented their outcome evaluation in a 
descriptive manner by the number individuals that participated in the following activities: 
”networking, methods training, on-the-job-training and community education” (p.4). 
While researchers were able to implement their studies and obtain data that would 
combat the community’s asthma problem, the community itself was able to benefit with a 
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well-trained research corps based within the community. The community outreach 
workers that were trained became empowered and had higher levels of confidence in 
their newly acquired skills (Tumiel-Berhalter, 2007).   The trained was an avenue for 
performance improvement. 
Although relationship-building was not quantified in this evaluation, Tumiel-
Berhalter et al. (2007) noted that using community members allowed for smoother 
research process since the study participants were more comfortable to give information 
to someone that they are familiar with within the community.  
An evaluation of capacity building efforts was conducted for leadership in the 
Public Health personnel in the United States. The program being evaluated emerged from 
a need of improved competencies in the area of public health in the United States. Due to 
recent terrorist attacks and threats, it was deemed necessary to enhance leadership 
capabilities for individuals in key position the field of public health (Saleh, Williams, & 
Balougan, 2004). It became obvious that, as a country, the United States could be 
vulnerable to a public health threat and that decision-makers needed to be skilled in 
leadership.  
The Northeast Public Health Leadership Institute (NEPHLI) introduced a 
leadership program that aimed at improving “public health performance, developing 
collaborative relationships and partnerships, risk communication, team building, group 
problem solving, responding to the needs for cultural diversity and competence and 
emergency preparedness training” (as cited in Saleh et al., 2004, p. 1245).  
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For the program evaluation study, the leadership program was evaluated through 
the use of survey taken by 114 program participants (Saleh et al., 2004). The participants 
self-reported their competencies before and after the leadership program. There was a 
link between the frequency of use the skills acquired during the training and the 
improvement of those skills over time (Saleh et al., 2004). A significant increase in 
leadership competencies, it should be noted that the self-reporting aspects of the survey 
may well have affected the results despite the significant increase in leadership 
competencies.  
Programs require some type of evaluation to inform decisions. However, it is 
necessary to design, plan and conduct the evaluation in a manner that will results in 
accurate and reliable evidence. Evaluating capacity building activities does not just apply 
to countries in the developing world. In Canada, it was noted that capacity building for 
health research was desperately needed in rural and remote areas (Miller, J., Mclean, L., 
Coward, P. & Broemeling, A-M, 2009). Miller et al., (2009) showed that if health 
workers and researchers are provided with an environment that fosters the conduct of 
research, it is likely that the amount of research undertaken will increase and evidence 
from research can be used in decision making. Various areas were pinpointed for the 
implementation of capacity building activities. Many of the stakeholders expressed a 
need for “enhanced communication of health results, research education, and networking 
opportunities” (Miller et al., 2009, p. 2).  
Capacity building initiative ought to take a comprehensive approach.  Miller et 
al., (2009) highlighted the fact that it was not sufficient to teach staff how to implement a 
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research study, but it was crucial to also teach how to disseminate results and use them 
for community health decision or policy making (Miller et al., 2009, p. 2). In other 
words, once the research is completed and that reliable results are obtained it is necessary 
to apply those results strengthening health services in the area. Capacity building has 
more impact when an actual champion of the project is identified and tuned into the 
program (Miller et al., 2009).  In other words, the efforts are more effective with focused 
support. 
Other Program Evaluation Studies In Clinical Research 
There are a number of program evaluation studies in other research domains. 
Robinson & Trochim (2007) have recognized the importance of clinical trials in the 
improvement of health outcomes in the community, and pointed out that it is important to 
include minorities in clinical trials so as to authenticate the resulting treatments for 
minority populations since culture influences health behavior (Robinson & Trochim, 
2007). Low rates of clinical trials participation among minority populations in the US is 
evident (Robinson & Trochim, 2007). The US NIH even requires that recruitment and 
retention of minority participants in NIH-funded clinical trials due to an enacted law 
(Robinson & Trochim, 2007). This policy change occurred in order to effectuate a 
solution t designed to solve a problem, but it is important to understand why participation 
rates for clinical trials are low in minority communities. 
Robinson and Trochim (2007) attempted to understand the reasons for this issue 
from the source itself, – the community and other stakeholders. Various reasons are 
attributed to this problem, although the data were mostly obtained from researchers and 
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health professionals conducting research. Robinson & Trochim (2007) opted to study the 
barriers to minority participation in clinical trials (and other medical research) by 
investigating the perceptions of community members, researchers, and health 
professionals. All study participants were part of the National Cancer Institute’s Special 
Populations Networks.  
Robinson and Trochim (2007) used novel research tools such as concept mapping, 
a well-structured research tool that uses a participatory approach to data collection from 
stakeholders. Concept mapping allows for better “project planning, idea generation and 
structuring as well as interpretation of the stakeholder’s concepts on solutions for a 
common problem” (Robinson & Trochim, 2007, p.531). A special software application 
allowed the participants to brainstorm and make various statements about their 
perceptions. Robinson & Trochim then sorted and rated the statements. Through concept 
mapping analysis, maps were generated to show how all statements from the study 
sample clustered by theme. Robinson & Trochim (2007) concluded that the participants 
perceived the design and implementation of medical research study as a barrier and study 
also showed that limited, with insufficient attention was paid to patients’ concerns 
regarding their fears of clinical trials. 
Robinson & Trochim (2007) reiterated the importance of taking the perceptions of 
research participants into consideration in order to improve the impact of clinical trials 
for the targeted communities. Researchers, health professionals, and policy makers may 
have the best intentions, but the work may not be as beneficial as intended without 
addressing the research participants’ concerns.  
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Using Research to Build Capacity Strengthening Health Systems 
Research systems provide the evidence that is required for justifying the needed 
for improving health. The global health community continuously invests into health 
programs due to the urgent needs for better health outcomes throughout the globe. 
Particularly, developing countries stand to greatly benefit from health research as their 
health issues keep increasing in magnitude. Hanney & Block (2006) affirmed that, by 
innovating and collaborating, building health systems help in the conduct and use of 
information so to inform policy, improve health and close the gap in health equity. 
Hanney & Block encouraged conducting research on research in order to show evidence 
of impact of research on health (p.2). In response to the demands of meeting the 
Millennium Development Goals (established by the United Nations), an increasing 
amount of funds has been invested in improve health. Conducting research on the 
research that has been effectuated by these funds will show cost-benefits of the work 
(Hanney & Block, 2006). The impact of these investments is then weighed against the 
outcomes. 
Through an initiative led by the WHO, an international workshop on National 
Health Research Systems was held in Thailand in 2001 (Hanney & Block, 2006). The 
results of this workshop included a working definition of health research systems, 
potential strategies for strengthening these systems, as well as a way to evaluate their 
performance (Hanney & Block, 2006). Other discussions on building health research 
systems have included showing how evidence from health research is used and how to 
build a culture of research on research (Hanney & Block, 2006). 
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Partnerships are effective. Hanney & Block (2006) have also pointed out the need 
for the health communities to link up and collaborate with other sectors. For example, in 
order to investigate traffic accidents, it is necessary to work with transportation 
departments (Hanney & Block, 2006). The main area of concern in building research 
systems is human resources required to design, conduct, manage, analyze, and publish the 
studies. Recruiting, training, and retaining skilled staff is critical to building health 
research systems.  
Conclusion of Literature Review 
With the current increase in investment for capacity building in clinical research 
in Sub-Saharan African, the need for ethical and quality standards is being emphasized. 
Researchers are measuring quality assurance by collecting data against certain indicators 
based on GCP. Compliance with international standards is not only motivated by the need 
to conduct sound research, but it is also driven by the requirements to conduct research in 
harmony with the international health standards. However, few researchers have allowed 
research participants to have a say in the quality and ethics of the study, and additional 
research is required to explore the involvement of the participants in shaping the research 
and to ensure that their needs, as end-users, are being met. Involving the community in 
which the research is being conducted is critical to success of the study. The acceptability 
and longevity of the ensuing solution or intervention is also promoted when the 
community is earnestly involved throughout the study.  
With the number of capacity building efforts in health research and programs 
currently in place globally, evaluations of these projects are necessary. Assuming that 
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capacity building projects have measurable and observable indicators, quantitative 
evidence can be generated to show whether or not the projects are effective, efficient and 
being conducted as intended. 
Human research on the African continent is increasing and may be outpacing 
capacity building efforts. There is a need for a strategic approach in addition to the 
standard quality methods and tools to achieving study outcomes for large community 
based cohort studies and clinical trials in Africa and other parts of the developing world 
conducting clinical research. For the purposes of this project, the site in Kenya is 
conducting large-community based epidemiology studies in order to determine the 
incidence of TB in the target study population and/or TB vaccine trials. The next chapter 
includes a description of the methodological approach of this evaluation study that will 
utilize tools to measure the research site’s performance (a GCP checklist), the level of 
participants, satisfaction with research procedures, and the level of informed consent 
comprehension through questionnaires. 
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Chapter 3: Research Method 
This chapter provides a description of the study design as a descriptive cross-sectional 
study that intends to evaluate capacity -building efforts for a clinical research study in 
Western Kenya. The chapter includes the study site, population, and sample size 
considerations. It also describes methods for data collection and analysis, including the 
GCP checklist or GCP audit checklist, the participant satisfaction questionnaire, and 
informed consent comprehension questionnaire which are described as evaluation 
methods and tools. As for data analysis, the GCP audit checklist scoring- which scores 
the presence or absence of systems, processes, and documents required to conduct GCP 
compliant research - is used. The trending analysis that was conducted is fully described. 
In particular, participant satisfaction was assessed using a questionnaire to assess quality 
aspects of the research, such as participant-study staff interaction, usability of the 
documentation, physical infrastructure, convenience, accessibility, financial factors, 
procedures and tests, and flexibility of timing of procedures as determinants of 
participant satisfaction. Finally, a description of the Informed Consent Comprehension 
Questionnaire used in assessing the participant’s ability to remember or recall basic and 
foundational pieces of knowledge critical to the informed consent process is also 
described. 
General Study Design 
The study is a descriptive cross sectional one, the intent of which is to gather 
quantitative and qualitative data. The purpose of this study is to build appreciation of the 
elements of quality needing to be highlighted when conducting clinical research in 
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resource-limited environments and to obtain the participants’ opinion on the study 
conduct.  
The clinical research site underwent a quantitative assessment of GCP compliance. 
The assessment of GCP compliance was conducted by collecting and analyzing data 
using two separate tools:  
1. A GCP audit checklist scoring the presence or absence of systems, processes, 
and documents required to conduct GCP -compliant TB studies and covering 
six areas including document management, personnel and training, protocol 
adherence, data management compliance, monitoring, and laboratory 
compliance.  
2. A trending analysis database was built to show a historical collection of 
observations and comments from various reviews and assessments of the site 
and the study conduct. The historical data were compiled from deviation logs, 
audit reports, monitoring reports, and quality control reports of study 
databases from initiation of enrollment of the active epidemiological study 
until the time of data collection for this evaluation study.  
Completing the GCP checklist then provides for a means for a comparison of historical 
performance to the present time operations of the site and the study conduct in regards to 
compliance with GCPs. 
Participant satisfaction was assessed using a questionnaire that is based on an 
adapted version of the Patient Satisfaction Questionnaire Short-Form (PSQ-18), which is 
used in the health care field. The PSQ-18 was adapted for this evaluation study to best 
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suit an environment of research as opposed to a healthcare setting. The questionnaire was 
modified and translated into the main local language at the study site to promote 
comprehension by the population in Western Kenya. The psychometric properties of the 
PSQ-18 were assessed and the validity and reliability of the instrument were deemed 
acceptable (Marshall & Hays, 1994). The main determinants of participant satisfaction 
are their expectations and their characteristics such as social class, marital status, gender, 
age, and ethnicity. For this study, quality aspects such as participant-study staff 
interaction, usability of the documentation, physical infrastructure, convenience, 
accessibility, financial factors, procedures and tests, and flexibility of timing of 
procedures are also determinants of participant satisfaction (Marshall & Hays, 1994).  
Informed consent comprehension was evaluated using an adapted version of a tool 
developed by Minnies et al.  (2008). Some of the multiple choice questions in the 
assessment tool are designed to assess the participant’s ability to remember or recall basic 
and foundational pieces of knowledge critical to the informed consent process (Minnies 
et al. , 2008). The rest of the multiple choice questions were used to assess the 
participant’s understanding and its impact on the decision-making of being involved in 
the research. A simple scoring system was used to gauge participants’ overall 
understanding of the informed consent procedure. The questionnaire includes 10 
questions, six of which are geared towards assessing understanding while the rest are 
used to evaluate recall of information on the informed consent form. The participant’s 
scored a point by choosing the correct answer in multiple choice questions. For the 
understanding questions, there is a maximum score of six and a minimum of zero. For the 
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recall questions, there is a maximum score of four and a minimum of zero. It is assumed 
that the concept of understanding and recall can overlap, so the questions categorized as 
understanding ones are those that assess the participant’s ability to grasp the meaning of a 
particular informed consent concept, and questions categorized as recall are those that 
assess the participant’s ability to bring back to mind or remember information provided 
during the informed consent process. 
Sample Size Considerations  
The participants in the current clinical studies and future clinical vaccine trials at 
the identified site in Kisumu, Kenya are minors, so the parents/guardians of study 
participants were approached to take part in the satisfaction and comprehension portion 
of the evaluation. The TB incidence study currently being conducted at the site in 
Western Kenya enrolls a minimum 1,500 infants participants The participants’ 
parents/guardians were approached to complete the participant assessment questionnaire 
when they attended the clinic for one of the study visits (i.e., enrollment visit, follow-up 
visit, clinical test visit).  
The sample for the satisfaction and comprehension portion of the study was 
drawn from the parents and guardians of the approximately 1,500 infants participating in 
the current Aeras Epidemiology Study. They are referred to here as participating parents 
and guardians. A random sample was drawn, based on every fourth participating parents 
or guardians whose child is attending a follow-up visit or a case verification ward visit 
(i.e., an enrollment visit, follow-up, or clinical test visit). This yielded at least 375 
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participants parents/guardians. A refusal/no-show rate of 10% was projected. Hence, 338 
were expected to agree to be enrolled for the participant satisfaction assessment 
At the time of data collection, the TB infant epidemiology study had already 
completed enrollment with a total of 2,900 participants enrolled. However, due to the 
sample size commitments made at the proposal stage of this evaluation study and also 
due to time constraints, a total of 324 participants were approached to participate in the 
evaluation study. Ten of them refused to participate and 17 consented but did not have 
the chance to have the questionnaire administered since they had run out of time from 
their scheduled visits. These 17 consented participants can be considered as “no-show” 
for the evaluation study. In the end, 297 consented participants completed the 
questionnaires. 
Evaluation Methods and Instruments 
GCP Compliance Assessment 
The assessment of GCP compliance was conducted by collecting and analyzing data 
using two separate tools.  
1. I conducted a GCP audit, an independent person/team not employed by the 
clinical research site. The audit included a checklist scoring the presence or 
absence of systems, processes, and documents required to conduct GCP compliant 
TB studies and covering six areas including document management, personnel 
and training, protocol adherence, data management compliance, clinical 
evaluations, and laboratory compliance. Each section was scored using a weighted 
score of each question/element. An overall score representing degree of GCP 
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compliance as measured by the audit tool was determined as well. The assessment 
tool was divided into six sections related to the six critical areas of compliance. A 
maximum score was determined for each section for each site based on applicable 
requirements/questions. The site was then assessed and scored based on degree of 
completion of each requirement/question. The scores was presented as 
percentages such as percent of findings related to documentation, percent of 
findings related to informed consent process, percent of findings related to data 
management and so on. There are no known researchers who have validated the 
GCP checklist. However, in the United States, it is a legal obligation, through the 
Code of Federal Regulations (21CFR312.120) to conduct clinical trials in 
compliance with GCP guidelines (FDA, 2006). One can thus assume that all FDA 
approved clinical trials have undergone a stringent GCP check such as the one 
proposed in this evaluation study.  
2. A trending analysis database was set-up where data were compiled from deviation 
logs, audit and monitoring reports (internal and external), and Quality Control 
(QC) checks of data. Data were compiled and used for this study starting from 
enrollment of active epidemiology study protocol) to 3 months from initiation of 
GCP audit. The data elements consisted of the number and the type of findings 
and observations found from each evaluation and assessment of the site and study 
performance. For example, an audit and monitoring report of a study includes a 
number of critical, major, and minor findings. These findings are meant to inform 
the site’s staff to correct deviations from guidelines and proper study conduct. 
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Some examples of data found in these databases include the number of informed 
consent form properly completed, number of errors in data capture, number of 
protocol amendments and their reason, and number of training files properly 
maintained, and so on. These data elements were then plotted against time so to 
show a historical trend. 
Every note of noncompliance or questionable alignment with GCP is considered either a 
finding or an observation. The distinction between the two is that a finding is directly 
related to an explicit GCP guideline and observations are thoughts or opinions of the 
auditor/ monitor not directly linked to a specific GCP guideline. A finding may not 
necessarily be negative; however, it is a point that ought to be noted by the research site. 
For the GCP checklist, a system of rating the seriousness of findings and observations is 
defined as follows: 
Critical finding: Finding with a high risk of having an impact in the analysis of 
the trial, the data integrity, or resulting in substantial risk of regulatory authority action 
towards the site or sponsor. 
Major finding: Finding that do not invalidate trial conduct but which represent a 
significant departure from the protocol or a stated ICH GCP guideline, regulation or SOP, 
with actual or potential effect on patient safety, data integrity or study outcome. 
Minor finding: Finding that represent a departure from the protocol or a stated ICH 
GCP guideline, regulation or SOP, with no or minimal impact on patient safety, data 
integrity or study outcome. 
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Overall performance of the site is related to a general statement of the functioning 
of the site in relation to conformity to guidelines and standards such as GCP. 
Performance was also assessed in regards to particular categories of GCP. These 
categories include the following: documentation management, personnel training, data 
management, protocol and protocol amendments, monitoring, corrective action and 
preventing action (CAPA), and laboratory. The GCP checklist includes a number of items 
to be accomplished from each category. Each check will constitute a fulfillment of a 
requirement. This list was graded with a weighted score as follows: four points for an 
item that had absolutely no findings, three points for an item with minor findings, two 
points for an item with major findings, one point for an items with critical findings, zero 
point if the item was completely absent. The data from each method were analyzed to 
generate an overall performance and individual category performance scores for the site 
as well as ranking of low performing categories. The categories with the lowest point 
were considered the lowest performing.  
Participant Satisfaction Assessment 
Baseline demographics of the participant and parents’ demographic characteristics 
(e.g., sex, village, age of participants, age of parents, participant’s occupation,) were 
summarized for all participants. Figure 2 outlines the approach for assessing participants’ 
satisfaction. This multifactorial approach is due to the various factors that may affect the 
participants’ perceptions of study processes. These factors include aspects that are 
intrinsic to the participants (i.e., participant’s characteristics), the study processes, the 
participant-staff interactions, as well as clinical settings.  
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Figure 2. Illustration of multifactorial causes of participant satisfaction  
 
A questionnaire was designed to obtain information on the experiences and 
perceptions of randomized study participants’ parents/ and guardians and 
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study (Appendix 1). The questionnaires were given to the parents/guardians of children 
enrolled in the TB epidemiology studies. Along with demographic information, the 
questions pertained to the following aspects of participant satisfaction: participant-study 
staff interaction, informativeness of the materials provided during the study, physical 
infrastructure of the facilities, convenience and accessibility of research study facilities, 
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aspects were considered as dependent variables. Validity of the data collection tools was 
shown by a panel of at least three experts that rated the appropriateness of the content of 
the questionnaires. Reliability was shown by testing and retesting a small convenience 
sample at the research study site. Trained independent interviewers administered 
questionnaire to the parents/guardians of the children enrolled into the TB epidemiology 
cohort study. 
 The following independent variables were considered primary: 
 Duration of participation in the epidemiology cohort study 
The following independent variables were considered secondary: 
 Age  
 Gender 
 Occupation 
 Level of education 
Data on participants’ satisfaction was summarized using means, medians, and 
percentages. Chi square tests were used to examine the relationship between satisfaction 
scores and participants’ demographic characteristics (i.e., duration in the study, gender, 
age, and so on). Chi square tests were also used to compare the proportions of 
participants who identified with each satisfaction aspect (i.e., general satisfaction, 
technical quality, staff interpersonal manner, communication, financial aspects, and 
accessibility and convenience). For example, it may be expected that participants of 
different age groups will identify equally with a satisfaction as such as technical quality. 
By calculating a chi square statistic of the proportions of younger versus that of older 
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participants who identify with a satisfaction aspect such as technical quality of research 
activities or not, an individual will be able to determine if there is a statistically 
significant relationship between age and satisfaction with technical quality. 
Univariate analysis was performed to determine the association of the response 
variables and the potential predictors (Lansimies-Antikainen et al., 2009). Univariate 
analysis was used to explore each variable (age, gender, duration in the study, profession, 
etc.) separately. The pattern of the response for each aspect of satisfaction was 
determined. The goal was to discern differences between the various satisfaction aspects 
from the variable representing the respondent. For example, the respondents with a 
duration of participation in the epidemiology cohort study of less than 1 year may be 
expected to have different score of satisfaction in some aspects than those who have 
participated in the study for a longer duration. 
When measured on a five-point Likert scale, average individual satisfaction 
ratings can be calculated for each identified satisfaction aspect. These average 
satisfaction scores range between 1 (all respondents rate the aspect as ‘strongly 
disagree’) and 5 (all respondents rate the aspect as ‘strongly agree’). The higher the 
score, the higher the satisfaction level with this aspect as valued by the participant. 
Satisfaction scores can also be viewed by looking at the percentage of participants that 
rate a particular aspect as strongly agree percentage can vary between 0 and 100%.  
 The demographic information of the sample is presented in percentage in terms of 
age, gender, occupation, and level of education (See Appendix 1, Table 14). 
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Selected relation between participants’ characteristics and the main satisfaction 
aspects (i.e., general satisfaction, technical quality, staff interpersonal manner, 
communication, financial aspects, and accessibility and convenience) was analyzed in 
relation to participants characteristics through chi square analysis (See Appendix 1, Table 
15). Duration of participation and staff experience with research was correlated with 
main satisfaction aspects.  
Informed Consent Comprehension 
The nature of clinical trials is to find out if harm will be done by a new drug, vaccine, 
or treatment. With such a paradox, it is necessary to apply strict guidelines to ensure the 
fairness of the studies, their conduct as well as the soundness resulting data. The idea of 
autonomy is the bioethics principle that serves as a guideline to ensure that human rights 
of the volunteers are respected. The principle of respect for autonomy requires the 
investigator to know that the research subject has the capacity to act intentionally, with 
understanding, and without controlling influences that would mitigate against a free and 
voluntary act. This principle is the basis for the practice of "informed consent" (Oduro et 
al., 2008). In order to assess the quality of informed consent in the evaluation of the site’s 
capacity to properly conduct clinical research, the participant needs to show an 
understanding and appreciation of the information provided to him/her during the 
informed consent process. 
For informed consent comprehension, questions were asked covering information 
presented when a participant was administered an informed consent form (Minnies et al. , 
2008). The questionnaire needed to ascertain whether or not the participants appreciate 
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the themes that are obligatory in an informed consent document for clinical research 
involving human beings. In order to ensure that the participant’s autonomy is respected, it 
is critical to ensure that the participants understood the following ideas: the background 
of the study, the study procedures, risks and benefits, confidentiality, the voluntary nature 
of participation in the study, and the right to withdraw at any time. The questionnaire has 
a multiple choice format and choosing the correct answer will indicate comprehension of 
the theme of the question.  
The following independent variables were considered primary: 
 duration of participation in the epidemiology cohort study 
 research experience of the study staff person that administered consent 
As in the participants’ satisfaction portion of the study, the following independent 
variables were considered secondary: 
 age 
 gender 
 occupation 
 level of education 
On the informed consent questionnaire, participants are expected to select the 
correct answer from a choice of five possible answers for each of the questions. One of 
the answers is an exact reflection of the information in the consent document or an 
expected answer according ethics standards, which, if selected, was taken as an indicator 
of correct understanding or recall (Minnies et al. , 2008). The percent of correct answered 
is then used an indicator of the level of comprehension of the question from participants 
  
58
(See Appendix 1, Table 4). Data on participant informed consent comprehension were 
summarized using percentages Duration of participation and experience of staff 
administering consent was correlated with the correctness of informed consent answers. 
Selected relation between participants’ characteristics and main satisfaction aspects are 
analyzed using chi-square analysis (see Table 6, Appendix 1). 
Data Analysis Tools 
It was originally proposed that data would be entered into EpiInfo databases and 
analysis will be done using STATA for this evaluation study. However, on the field, 
these software were not available. Hence, for both the participant satisfaction and 
informed consent comprehension, the data management was performed with SQL server 
management studio while statistical analysis was done using SAS Version 9.2 
Study Procedures 
Study Setting 
This evaluation of the capacity building program was conducted at the 
KEMRI/CDC Field Research Station in Karemo Division, Siaya District in Western 
Kenya. The site is located in rural area. The Karemo district occupies an area of 235.1 
km2 with a population of 76,986 (Ministry of Finance and Planning, Republic of Kenya, 
2010). This site has been involved in clinical research since 1979 in collaboration 
between the Kenya Medical Research Institute (KEMRI) and the U.S. CDC (2010). 
Although the site was originally known for its Malaria research, it has recently been 
involved in HIV, TB, and other research areas. In particular, the site is known for the 
conduct of a third phase trial of the world’s most clinically advanced malaria vaccine 
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candidate, known as RTS,S. For preparation for the conduct of TB vaccine efficacy 
study, the site conducted epidemiology cohort studies in adolescents and in infants.  
Inclusion/Exclusion Criteria 
Inclusion criteria. The inclusion criteria for the participant satisfaction 
assessment and informed consent comprehension are 
 Parent of a participant currently enrolled in or withdrawn from a current large-
community based TB infant epidemiology study protocol at the site  
 Willingness to provide informed consent 
Exclusion criterion. The exclusion criterion for the participant satisfaction 
assessment and informed consent comprehension is an unwillingness to provide informed 
consent. 
Participant Entry Procedures 
Three hundred and twenty-four parents of baby participants currently enrolled or 
withdrawn from the active TB epidemiology study were approached to be administered 
the participant satisfaction and informed consent comprehension questionnaires. This 
study was nested in an active TB infant epidemiology protocol at the site and participants 
were randomly selected from enrollment logs and from scheduled study visits lists. The 
active epidemiology study consists of enrollment at Day 0 and then home visits at 
specific intervals for two years. Participants were recruited during the regularly scheduled 
study visits of the active epidemiology study at the clinic. A staff member of the active 
epidemiology study conducting the visits was designated as recruiter. Each recruiter was 
issued blocks of study identification numbers depending on the projected number to be 
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enrolled. During recruitment or during the visit of the active epidemiology study, 
participants were informed, by the active epidemiology study staff (recruiter) of the 
present evaluation study and were asked to participate in the present study. If the 
participant gave voluntary consent to be in the study, the participant satisfaction and 
informed consent comprehension questionnaires were administered at this point. 
Ethical Considerations 
This capacity building evaluation study was reviewed and approved by the 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC) of each 
institution with ethical oversight on the research site, including the KEMRI and the 
Walden University IRB reviewed and approved this evaluation study. All participants are 
parents/guardians of the children that are enrolled in the TB epidemiology study that was 
being conducted at the site. Recruitment into the evaluation study occurred during a 
regularly scheduled TB epidemiology study visit. The nature of the evaluation study was 
explained to the participants and participants were informed that participation is 
voluntary and that they can withdraw at any time. Written informed consent was obtained 
from each participant prior to entry into the evaluation study. The consent form was 
translated in the local language(s) and back translated into English to ensure accuracy. A 
copy of the signed consent form was given to every participant and the original was 
maintained with the participant’s records. 
All study records are kept in a locked file cabinet and code sheets linking a 
participant’s name to a participant identification number are stored separately in another 
locked file cabinet. Researchers also complied with all applicable privacy regulations 
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such as the Health Insurance Portability and Accountability Act of 1996 or the EU Data 
Protection Directive 95/46/EC. 
Any documents that the IRB/IEC may need to fulfill its responsibilities, such as 
protocol amendments, and information concerning participant recruitment, payment or 
compensation procedures, or information from researchers was submitted to the IRB/IEC. 
The IRB/IEC’s written unconditional approval of the study protocol and the informed 
consent form was in the possession of the researcher before the study is initiated.  
Protocol modifications or changes could not be initiated without prior written 
IRB/IEC approval except when necessary to eliminate immediate hazards to the 
participants or when the change(s) involves only logistical or administrative aspects of 
the study.  
Summary 
Chapter 3 included the general study design as a descriptive cross sectional one 
that will use a GCP checklist, a trending analysis and questionnaires for both the 
participant satisfaction and the informed consent comprehension. GCP checklist and 
trending analysis were analyzed with descriptive statistics such as percentages.  The 
participant satisfaction and informed consent comprehension assessments were analyzed 
with descriptive statistics. Chi square analyses were performed to evaluate the association 
between independent variables such as age, occupation, level of education with 
dependent variables such as the level of satisfaction or the level informed consent 
comprehension. 
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Chapter 4 will detail the results and present them in tabular and text form as 
necessary with the data analysis elements that were specified in Chapter 3.  
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Chapter 4: Results 
In this chapter, data analysis and study findings are presented. Sections include an 
analysis of the study sample demographics, an analysis of the results of the GCP 
checklist scores, a trending analysis comparing current and historical observations and 
findings on compliance, an analysis of the participations satisfaction survey data, an 
analysis of the informed consent comprehension data, and a summary of all results.  
Analysis of Study Sample Demographics 
Descriptive statistics were used to describe the study sample demographics. There 
were 297 participants in the study. They were all females, which is consistent with the 
idea that, in the area where the infant TB study is being conducted, it is mothers who 
usually take their children to seek health care. There were no men in the study sample. As 
shown in Table 1, there were four age categories. Of those, 46.46% were younger than 25 
years (n= 138), 41.41% were between 25 and 35 years old (n=123), 11.11% were older 
than 35 years (n= 33), and 1.01% did not mark their age (n=3). The mean age was 26.2 
(SD 6.8) and the age median was 25. 
Table 1 
Age Distribution in the Study Sample 
Age % (n) 
Less than 25 years 
old 46.46 (138) 
Between 25-35 
years old 41.41 (123) 
Older than 35 years 
old 11.11 (33) 
Unknown 1.01 (3) 
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Table 2 shows the occupations represented. There were eight categories: 55.56% 
not working-- housewife (n= 165), 33.67% farming (n= 100), 7.74% business owner (n= 
23), 1.01% other (n=3), 0.67% unskilled labor (n= 2), 0.67% unknown (n=2), 0.34% 
salaried worker (n=1), and 0.34% skilled labor (n= 1).  
Table 2 
Occupation 
Occupation % (n) 
Farming  33.67 (100) 
Fishing  0 (0) 
Salaried worker (e.g. teacher, nurse, 
office) 0.34 (1) 
Business owner  7.74 (23) 
Skilled labor (e.g. carpenter, tailor) 0.34 (1) 
Unskilled labor (e.g. construction)  0.67 (2) 
Not working (housewife) 55.56 (165) 
Unknown 0.67 (2) 
Other 1.01 (3) 
 
As for the level of education in the study sample, as shown in Table 3, 85.19% had at 
least a primary school education (n=253), 9.43% had at least a secondary school 
education (n=28), 3.37% had no education (n= 10), 1.01% had a postsecondary education 
and for 1.01% (n=3), the education was unknown.  
Table 3 
Level of Education 
Level of Education % (n) 
None 3.37 (10) 
Primary 85.19 (253) 
Secondary 9.43 (28) 
Postsecondary 1.01 (3) 
Unknown 1.01 (3) 
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In terms of the participants’ duration into the study, 100% of the study participants had 
been in the study for less than 12 months and no participants (n=0) had been in the study 
for more than 1 year. 
Analysis of the Results of the GCP Checklist Scores 
The GCP checklist consisted of a list of items to be checked off if present at the 
site. This list was graded with a weighted score as follows: four points for an item that 
had absolutely no findings, three points for an item with minor findings, two points for an 
item with major findings, one point for items with critical findings, zero points if the item 
was completely absent. As a whole, the site scored had a score of 94.24 % (622/660) on 
the GCP check list. Details on the scores are shown in Appendix 2. There were no major 
or critical findings.  
According to the completed GCP evaluation, the entire site is well organized, with 
adequately trained staffed, clean and secured facilities, up-to-date equipment and 
procedures, a solid quality management system, and it is mainly compliant with local and 
international guidelines. According to the completed GCP checklist, for practices related 
to document management, the study site is satisfactory. There was a document control 
system in place that included standard operating procedures, SOPs, in a standardized 
form for all functions of the clinical research study such as laboratory, clinical operations, 
field operations, data management, ethics, and regulatory as well as QA. Except for 
laboratory SOPs, original SOPs were stored in the QA office in locked cabinets. 
Controlled copies of the SOPs were available at each functional area work station. Each 
SOP included an author, a reviewer, supervisory approval, and QA review and approval. 
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SOPs and their related forms were uniquely numbered. SOPs that became obsolete were 
stored in separate binder by the QA manager. There was a change control procedure that 
ensured that any modification to a controlled document was captured and sent through 
the appropriate approval procedure prior to the implementation of the change. Archiving 
and storage of study document was described in SOPs. The archiving and storage 
procedure included identification, storage, protection, retrieval, retention, and disposition 
of records. All study documents with confidential study information were stored in 
secured areas with restricted access. 
 The next GCP checklist area examined was personnel and training. The site had 
written procedures and documentation for all staff involved in the clinical research study. 
Each position was depicted in the organization chart. Job descriptions were included in 
each staff’s members training file. However, the site failed to generate and maintain a 
training matrix that specified details on training activities required for each study staff 
member. This was a minor finding. The training matrix would have allowed a way to 
ensure each staff member is qualified, experienced, and trained in their applicable duties. 
The staff was organized such that each position had at least more than one staff member 
capable of performing each function in the study. This redundancy prevented for gaps in 
case of extended absence of a staff member. Performance reviews were usually 
conducted annually and they seemed to occur on time since the majority of staff was on 
yearly contracts and their employment into the study could not continue without the 
results of the yearly performance review. Quality control personnel frequently monitored 
all study activities and their reports fed into each staff’s performance review. 
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In the data management sections, data were mainly captured electronically, even 
though paper forms were used as back-up in case of failure of the electronic system. The 
electronic data management system ensured and documented that the electronic data 
processing system conformed to the established requirements for completeness, accuracy, 
reliability, and consistent intended performance. Although data management SOPs were 
still in draft form, instructions on entering and maintaining data were available. Not 
having finalized SOPs is a minor finding. The data systems were designed to permit data 
changes in such a way that changes are documented, and that there is no deletion of 
entered data (i.e., audit trail, data trail, and edit trail). The system was secure and 
prohibited unauthorized access to the data. A list of the individuals who are authorized to 
make data changes was maintained. The data were backed-up in a secure server on a 
daily basis. There were a couple of major findings related to the lack of finalized data 
management and statistical analysis plans. Although these plans existed and were being 
used, they were formally approved as required by GCPs. 
In the portions related to protocol and amendments, the regulatory aspects seemed 
to be in order. There was an approved protocol on file that was kept by the QA 
department. The participant enrollment log was maintained in electronic form in the 
database and it was complete as it showed all 2,900 participants that had been enrolled 
into the study. There was also a monitoring log in place that showed that monitoring was 
being conducted on a quarterly basis. The delegation of responsibility was clear.  All 
correspondence with Ethics Review Committees (ERCs) and IRBs was kept in the 
investigator’s file. Protocol amendments and deviation reports were also on file. 
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Participants’ recruitment procedures were detailed in an SOP, which included a 
description of how the potential participants were identified, how the contact was made, 
and who made the contact. 
 A review of 5% of the 2,900 (n=150) completed informed consent forms of the 
infant TB study was conducted as part of this evaluation. The forms themselves were 
valid as they were the versions included in the last protocol approved by the ERCs and 
IRB. The 150 informed consent forms were reviewed for authenticity of signature and 
validity of the consent process. In some of the forms, when the participants were not able 
to read, the staff printed the participant’s name in the place of signature. However, the 
participants still have their thumb print put on the forms and a third party also witnessed 
the consenting procedure. Enrollment notes were written for each participant and it was 
documented that a signed copy of the consent form was given to each participant. The 
eligibility criteria (inclusion/exclusion) were defined in the protocol and set-up for entry 
in the electronic data entry screen.  
During enrollment, a participant would have had to fulfill the eligibility criteria 
before being able to proceed to any subsequent data entry screens for the study. This 
safeguard ensured that study data were collected only on participants that met the 
eligibility criteria. The case report forms (data collection tools) were also electronic. 
Prescreening and enrollment data were collected electronically on Personal Digital 
Assistants (PDAs), which is a hand held small computer resembling a palm pilot. This 
device allowed for enrollment nurses to move around and go from house to house without 
being encumbered by laptops. Data from subsequent study follow-up visits, however, was 
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collected on laptops through software that was downloaded to a server at the main site 
facility. The electronic case report forms (eCRFs) contained all parameters required by 
the protocol. The system allowed for an electronic signature each time it was accessed by 
a staff member. Anytime there was change in the data, the signature feature allowed for 
an audit trail to be generated since each entry left an electronic record. There were 
defined levels of access for the relevant staff members allowed to manipulate the 
database. For example, the nurses were only allowed to enter data. Supervisors and the 
principal investigator were allowed to modify data solely after a change control was 
completed and approved. In case of deviations, which are departures from the agreed to 
procedures or the protocol, there were written procedures for CAPA that included the 
completion of forms for recording infringements and the ensuing corrective plan as well 
as a timeline for correction. The QC and QA personnel were in charge of monitoring the 
corrections and reporting them to the principal investigator and the ethics committees. 
After correcting a deviation, a paper record was kept by the QA department. 
 In the laboratory, the main finding was related to the actual laboratory performing 
the tests for study samples that had not completed the accreditation process. This is 
considered a minor finding since its impact does not necessarily lead to any regulatory 
infraction nor does it impact data integrity or study outcome. There were minor findings 
were related to documentation. For example, a key instrument for the epidemiology 
study, the Genexpert instrument, required to assess samples for the presence of 
mycobacterium TB, did not have its own SOP document. The calibration log did not 
contain a separate log for a critical instrument such as the Hain twincubator, which is the 
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instrument that allows for hybridization of samples suspected of infection with 
mycobacterium TB. In one instance, the monthly maintenance log was missing the March 
2011 record for one of the autoclaves. In the SOPs, there were forms included as 
appendices, but the forms did not have the corresponding SOP number on them. The 
SOPs themselves did not have titles on each page. An SOP specifying a backup plan in 
case of equipment failure did not seem to exist. This SOP is expected to describe the 
availability and the accessibility of alternate equipment or plan for dealing for each piece 
of equipment. There does not seem to be health check plan for staff members who are 
exposed to risk of infection. For example, since staff members are handling the TB 
infectious agent, they should be tested for TB on a frequent basis. All findings mentioned 
above were considered minor. 
Other findings were minor, but still had to be mentioned since they are findings 
nonetheless. An example of these findings is related to documentation. The SOP books 
all included table of contents with no page numbers. So, from the table of contents, it was 
impossible to easily find specific SOPs in the books. The GCP checklist was then 
examined in terms of percent of findings and observations related to the main areas of 
GCP compliance as shown in Figure 3. 
 
  
71
 
 
Figure 3. Findings and observations from GCP checklist audit  
 
The laboratory was the study area with the most findings (46%), followed by data 
management (23%), personnel and training (15%), monitoring (8%), protocol and 
protocol amendments (8%), and document management (0%). On the GCP checklist, the 
laboratory had the most items to be checked which might explain the higher percentage in 
terms of findings and observations. 
 
Trending Analysis on GCP Compliance 
A trending analysis was performed where deviation logs, audit and monitoring 
reports (internal and external) were reviewed in order to identify the number of findings 
and observations of aspects of the study that were not compliant with GCP. In this 
dissertation the research question regarding trending analysis specified that only records 
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of the past 2 years were going to be examined. It was decided to go back to the first 
external GCP assessment of 2008 since, as this dissertation was being prepared, the 
intention was to started data collection in 2010. The 2008 report is crucial to report the 
actual progress of the site’s performance in terms of capacity building for the proper 
conduct of clinical trials in compliance with GCPs.  
Three past reports were found on site and they were reviewed to extract the 
number of findings and observations reported for the site’s status of compliance with 
GCPs. The first report was a thorough assessment that was conducted by an external 
auditor in September 2008. The other two reports were prepared by an internal monitor 
whose responsibility was to ensure that the study protocol was being followed; that 
changes to the protocol were being approved by the ethics committees; that the records 
being maintained were current, accurate, and complete; and that the investigator was 
carrying out the agreed-upon activities and had not delegated them to other previously 
unspecified staff. The monitoring reports reviewed were from monitoring visits 
performed in April 2009 and January 2010. The two monitoring reports and the external 
assessment report were then trended against the GCP checklist audit that was conducted 
as part of this dissertation study in January 2012. Table 4 below, shows the number 
findings and observations on GCP compliance from the four reports were reviewed for 
trending analysis.  
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Table 4 
Number of Findings and Observations from 2008-2012 
  
Documen
t 
Manage-
ment 
Personnel & 
Training 
Data 
Manage-
ment  
Protocol & 
Protocol 
Amend-
ments 
Moni-
toring 
Labora-
tory TOTAL 
External 
audit 
Sept. 
2008 6 0 9 21 5 7 48 
Internal 
Monitor-
ing Apr. 
2009 3 3 3 5 3 3 20 
Internal 
Monitor-
ing Jan. 
2010 5 4 1 4 0 6 20 
GCP 
checklist 
Audit 
Jan. 2012 0 2 3 1 1 6 13 
TOTAL 14 9 16 31 9 22   
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Table 4 shows that the total number of findings and observations decreased by 
73% (from 48 to 13) from September 2008 to January 2012 which shows significant 
improvement in terms of the site’s performance in terms of compliance with GCPs. As 
shown in the Figure 4, in general, the trend of observations and findings tends to decrease 
from the first (2008) to the last report (2012) reviewed.  
 
 
Figure 4. Trending Analysis of GCP Findings and Observations from 2008-2012  
 
 
Figure 5 shows that the GCP area of protocol and protocol amendments had the 
most finding and observations (n=31), followed by the laboratory (n=22), data 
management (n=16), document management (n=14), and then personnel and training and 
monitoring (both n=9).  
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Figure 5. Number of findings and observations per GCP area from 2008-2012 
 
Figure 5 shows that the area of protocol and protocol amendments (protocol adherence) is 
the one that seems to be the most noncompliant throughout the years and it should 
therefore be the areas with the most concentrated efforts for improvement. Altogether, the 
site’s audit against the GCP checklist was successful; it showed that the level of 
compliance with international standards in the conduct of clinical research was relatively 
high despite a few minor findings. The site had improved in compliance level since the 
first assessment in 2008. 
Analysis of the Participants’ Satisfaction Survey 
Clinical study participants’ satisfaction was measured in categories related to 
level of contentment with various aspects of satisfaction. For the general satisfaction 
categories, 97.31% of the study participants either strongly agreed or agreed that the 
attention received from the study staff while they interact was just about perfect. In terms 
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of staff interaction, 78.45% of participants either disagreed or strongly disagreed that they 
were dissatisfied with some things about the interactions that they had with study staff. 
The results of the series of questions related to the technical quality of the services 
provided during the trial were consistent with a high level of satisfaction. For the 
suitability of the environment, 90.57% of the participants either strongly agreed or agreed 
that the study staff and their facilities have everything needed for the study. For 
reassurance, 91.24% either disagreed or strongly disagreed that sometimes study staff 
make the wonder if the study is worthwhile. For staff dexterity, 95.62% of participants 
either strongly agreed or agreed that the staff was careful to check that they were satisfied 
when they were being examined by the study staff. For the study worth, 86.19% either 
disagreed or strongly disagreed that they have some doubts about the need for the TB 
epidemiology study in the community. For clarity, 82.16% of participants either strongly 
disagreed or disagreed that sometimes study staff used medical words without explaining.  
The results of the questions related to interpersonal manners also showed a high 
level of satisfaction. For those questions, 70.37% of study participants either strongly 
disagreed or disagreed that study staff were too businesslike and impersonal toward them; 
88.56% either strongly agreed or agreed that study staff treat them in a friendly and 
courteous manner; 77.1% either strongly disagreed or disagreed that study staff 
sometimes hurry too much during the study visits; and 92.93% either strongly agreed or 
agreed that study staff usually spend plenty of time with me.  
The next questions were related to communications and the level of satisfaction 
was consistently high. For those questions, 97.65% either strongly agreed or agreed that 
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study staff was good about explaining reasons for the research study, and 89.57% either 
strongly disagreed or disagreed that study staff sometimes ignore what they told them.  
The level of satisfaction remained high on questions related to financial aspects. 
For those, 98.99% either strongly agreed or agreed that felt confident that they can 
complete all study visits without spending too much money; 96.3% either strongly 
disagreed or disagreed that they have to spend more than they can afford to be part of this 
study. In terms of accessibility and convenience, the study participants were still 
consistently satisfied, and 97.98% either strongly agreed or agreed that the study visit 
hours are convenient for them. Moreover, 93.26% either strongly agreed or agreed that 
they have easy access to study staff when they need to. And finally, 90.91% % either 
strongly disagreed or disagreed that they find it hard to reach the study staff right away 
when they need to. The participants’ satisfaction data are represented in Table 5. 
  
78
Table 5 
Participant Satisfaction Survey Results 
 
Participant Satisfaction Aspect N (%) 
 
Strongly 
Agree Agree Uncertain Disagree 
Strongly 
Disagree
General Satisfaction      
The attention that I receive 
from the study staff while we 
interact is just about perfect 
173 
(58.25) 
116 
(39.06) 0 (0) 5 (1.68) 3 (1.01) 
 
I am dissatisfied with some 
things about the interactions 
that I have with study staff 
17 
(5.72) 
43 
(14.48) 4 (1.35) 
123 
(41.41) 
110 
(37.04) 
 190 159 4 128 113 
Technical Quality      
I think the study staff and their 
facilities have everything 
needed for the study 
187 
(62.96) 
82 
(27.61) 22 (7.41) 6 (2.02) 0 (0) 
Sometimes study staff make 
me wonder if the study is 
worthwhile 7 (2.36) 
12 
(4.04) 7 (2.36} 
130 
(43.77) 
141 
(47.47) 
When study staff examine me, 
they are careful to check that I 
am satisfied 
167 
(56.23) 
117 
(39.39) 0 (0) 
12 
(4.04) 1 (0.34) 
I have some doubts about the 
need for this study in the 
community 
11 
(3.70) 
18 
(6.06) 12 (4.04) 
124 
(41.75) 
132 
(44.44) 
Sometimes study staff use 
medical words without 
explaining 
25 
(8.42) 
23 
(7.74) 5 (1.68) 
101 
(34.01) 
143 
(48.15) 
Interpersonal manners      
Study staff are too businesslike 
and impersonal toward me 
37 
(12.46) 
48 
(16.16) 3 (1.01) 
93 
(31.31) 
116 
(39.06) 
(continued) 
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Participant Satisfaction Aspect N (%) 
 
Strongly 
Agree Agree Uncertain Disagree 
Strongly 
Disagree
Interpersonal Matters (cont’d) 
Study staff treat me in a friendly 
and courteous manner 
153 
(51.52) 
110 
(37.04) 0 (0) 
26 
(8.75) 8 (2.69) 
Study staff sometimes hurry too 
much during the study visits 
26 
(8.75) 
32 
(10.77) 10 (3.37) 
120 
(40.40) 
109 
(36.70) 
Study Staff usually spend plenty 
of time with me 
154 
(51.85) 
122 
(41.08) 2 (0.67) 
17 
(5.72) 2 (0.67) 
Communication      
Study staff is good about 
explaining reasons for the 
research study 
228 
(76.77) 
62 
(20.88) 1 (0.34) 4 (1.35) 2 (0.67) 
Study staff sometimes ignore 
what I tell them 8 (2.69) 
21 
(7.07) 2 (0.67) 
110 
(37.04) 
156 
(52.53) 
Financial Aspects      
I feel confident that I can 
complete all study visits without 
spending too much money  
245 
(82.49) 
49 
(16.50) 0 (0) 3 (1.01) 0 (0) 
I have to spend more than I can 
afford to be part of this study 5 (1.68) 4 (1.35) 2 (0.67) 
73 
(24.58) 
213 
(71.72) 
Accessibility and Convenience      
The study visit hours are 
convenient for me 
197 
(66.33) 
94 
(31.65) 1 (0.34) 3 (1.01) 2 (0.67) 
I have easy access to study staff 
when I need to 
175 
(58.92) 
102 
(34.34) 3 (1.01) 
14 
(4.71) 3 (1.01) 
I find it hard to reach the study 
staff right away when I need to 7 (2.36) 
15 
(5.05) 5 (1.68) 
88 
(29.63) 
182 
(61.28) 
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Next, Tables 6 through 8 illustrate the relationship between participants’ 
characteristics and the main satisfaction aspects (i.e., general satisfaction, technical 
quality, staff interpersonal manner, communication, financial aspects and accessibility & 
convenience). During data analysis, it was found that, in terms of comparing the 
difference in the satisfaction levels according to occupation, it was best to compare 
housewives vs. other occupations as opposed to farming versus other as originally 
proposed. This change was made due to the fact that the majority of the participants were 
housewives (55.56%). Table 6 shows that in terms of age, the level of satisfaction is high 
in both age groups (≤25 vs. > 25) in all questions. Due the high p-values in these data, the 
difference in the level of satisfaction between the age groups may not be significant. 
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Table 6 
Management of Data for the Relationship between Age and Main Satisfaction Aspects 
 
  Age group  
P value  Satisfaction Item ≤ 25 >25 
The attention that I receive from the study staff 
while we interact is just about perfect  
 
 
Agree 151(51.36%) 135(45.92%) 0.8758 
Disagree 4(1.36%) 4(1.36%)  
I am dissatisfied with some things about the 
interactions that I have with study staff  
 
 
Disagree 123(41.84%) 112(38.10%) 0.7942 
Agree 32(10.88%) 27(9.18%)  
I think the study staff and their facilities have 
everything needed for the study  
 
 
Agree 141(47.96%) 125(42.52%) 0.7617 
Disagree 14(4.76%) 14(4.76%)  
Sometimes study staff make me wonder if the 
study is worthwhile  
 
 
Disagree 144(48.98%) 130(44.22%) 0.8325 
Agree 11(3.74%) 9(3.06%)  
When study staff examine me, they are careful 
to check that I am satisfied  
 
 
Agree 149(50.68%) 132(44.90%) 0.6276 
Disagree 6(2.04%) 7(2.38%)  
I have some doubts about the need for this 
study in the community  
 
 
Disagree 132(44.90%) 132(44.90%) 0.0056 
Agree 23(7.82%) 7(2.38%)  
Sometimes study staff use medical words 
without explaining  
 
 
Disagree 130(44.22%) 115(39.12%) 0.7939 
Agree 25(8.50%) 24(8.16%)  
Study staff are too businesslike and impersonal 
toward me  
 
 
Disagree 104(35.37%) 104(35.37%) 0.1461 
Agree 51(17.35%) 35(11.90%)  
(continued) 
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  Age group    
P value Satisfaction Item ≤ 25 >25 
Study staff treat me in a friendly and courteous 
manner  
 
 
Agree 135(45.92%) 124(42.18%) 0.5767 
Disagree 20(6.80%) 15(5.10%)  
Study staff sometimes hurry too much during the 
study visits  
 
 
Disagree 127(43.20%) 110(37.41%) 0.5445 
Agree 28(9.52%) 29(9.86%)  
Study Staff usually spend plenty of time with me    
Agree 143(48.64%) 130(44.22%) 0.6736 
Disagree 12(4.08%) 9(3.06%)  
Study staff is good about explaining reasons for 
the research study  
 
 
Agree 148(50.34%) 138(46.94%) 0.0458 
Disagree 7(2.38%) 1(0.34%)  
Study staff sometimes ignore what I tell them    
Disagree 132(44.90%) 132(44.90%) 0.0056 
Agree 23(7.82%) 7(2.38%)  
I feel confident that I can complete all study 
visits without spending too much money   
 
 
Agree 154(52.38%) 137(46.60%) 0.4990 
Disagree 1(0.34%) 2(0.68%)  
I have to spend more than I can afford to be part 
of this study  
 
 
Disagree 151(51.36%) 134(45.58%) 0.6135 
Agree 4(1.36%) 5(1.70%)  
The study visit hours are convenient for me    
Agree 152(51.70%) 136(46.26%) 0.8927 
Disagree 3(1.02%) 3(1.02%)  
I have easy access to study staff when I need to    
Agree 146(49.66%) 129(43.88%) 0.6290 
Disagree 9(3.06%) 10(3.40%)  
I find it hard to reach the study staff right away 
when I need to  
 
 
Disagree 145(49.32%) 127(43.20%) 0.4779 
Agree 10(3.40%) 12(4.08%)  
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Table 7 shows that in terms of level of education, the level of satisfaction is high 
in both education levels (none vs. some) groups in all questions. Due the high p-values in 
these data, the difference in the level of satisfaction between the group with some 
education and the one with no education may not be significant. 
Table 7 
Management of Data for the Relationship between Level of Education and Main 
Satisfaction Aspects 
 
  Formal Education 
P value  Satisfaction Item None Some 
The attention that I receive from the study 
staff while we interact is just about perfect  
 
 
Agree 10(3.37%) 279(93.94%) 0.5925 
Disagree 0(0.00%) 8(2.69%)  
I am dissatisfied with some things about the 
interactions that I have with study staff  
 
 
Disagree 9(3.03%) 228(76.77%) 0.4137 
Agree 1(0.34%) 59(19.87%)  
I think the study staff and their facilities have 
everything needed for the study  
 
 
Agree 9(3.03%) 260(87.54%) 0.9498 
Disagree 1(0.34%) 27(9.09%)  
Sometimes study staff make me wonder if 
the study is worthwhile  
 
 
Disagree 10(3.37%) 267(89.90%) 0.3874 
Agree 0(0.00%) 20(6.73%)  
When study staff examine me, they are 
careful to check that I am satisfied  
 
 
Agree 8(2.69%) 276(92.93%) 0.0140 
Disagree 2(0.67%) 11(3.70%)  
(continued) 
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P value Satisfaction Item None Some 
I have some doubts about the need for this 
study in the community  
 
 
Disagree 10(3.37%) 257(86.53%) 0.2809 
Agree 0(0.00%) 30(10.10%)  
Sometimes study staff use medical words 
without explaining  
 
 
Disagree 8(2.69%) 240(80.81%) 0.7615 
Agree 2(0.67%) 47(15.82%)  
Study staff are too businesslike and impersonal 
toward me  
 
 
Disagree 5(1.68%) 205(69.02%) 0.1433 
Agree 5(1.68%) 82(27.61%)  
Study staff treat me in a friendly and courteous 
manner  
 
 
Agree 8(2.69%) 254(85.52%) 0.4124 
Disagree 2(0.67%) 33(11.11%)  
Study staff sometimes hurry too much during 
the study visits  
 
 
Disagree 8(2.69%) 231(77.78%) 0.9695 
Agree 2(0.67%) 56(18.86%)  
Study Staff usually spend plenty of time with 
me  
 
 
Agree 9(3.03%) 267(89.90%) 0.7132 
Disagree 1(0.34%) 20(6.73%)  
Study staff is good about explaining reasons 
for the research study  
 
 
Agree 10(3.37%) 279(93.94%) 0.5925 
Disagree 0(0.00%) 8(2.69%)  
(continued) 
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P value Satisfaction Item None Some 
Study staff sometimes ignore what I tell them    
Disagree 10(3.37%) 257(86.53%) 0.2809 
Agree 0(0.00%) 30(10.10%)  
I feel confident that I can complete all study 
visits without spending too much money   
 
 
Agree 9(3.03%) 285(95.96%) 0.0038 
Disagree 1(0.34%) 2(0.67%)  
I have to spend more than I can afford to be 
part of this study  
 
 
Disagree 10(3.37%) 278(93.60%) 0.5696 
Agree 0(0.00%) 9(3.03%)  
The study visit hours are convenient for me    
Agree 9(3.03%) 282(94.95%) 0.0681 
Disagree 1(0.34%) 5(1.68%)  
I have easy access to study staff when I need to    
Agree 9(3.03%) 269(90.57%) 0.6358 
Disagree 1(0.34%) 18(6.06%)  
I find it hard to reach the study staff right away 
when I need to  
 
 
Disagree 9(3.03%) 266(89.56%) 0.7501 
Agree 1(0.34%) 21(7.07%)  
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Table 8 shows that in terms of occupation, the level of satisfaction is high in 
housewives and in participants of other occupations in all questions. Due the high p-
values in these data, the difference in the level of satisfaction between the housewives 
and the participants of other occupations may not be significant. 
Table 8 
Management of Data for the Relationship between Occupations and Main Satisfaction 
Aspects 
 
  Occupation  
P value  Satisfaction Item House wife Other 
The attention that I receive from the study 
staff while we interact is just about perfect  
 
 
Agree 160(53.87%) 129(43.43%) 0.6886 
Disagree 5(1.68%) 3(1.01%)  
I am dissatisfied with some things about 
the interactions that I have with study staff  
 
 
Agree 135(45.45%) 102(34.34%) 0.3323 
Disagree 30(10.10%) 30(10.10%)  
I think the study staff and their facilities 
have everything needed for the study  
 
 
Agree 150(50.51%) 119(40.07%) 0.8243 
Disagree 15(5.05%) 13(4.38%)  
Sometimes study staff make me wonder if 
the study is worthwhile  
 
 
Agree 155(52.19%) 122(41.08%) 0.6046 
Disagree 10(3.37%) 10(3.37%)  
(continued) 
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Occupation  
  
P value Satisfaction Item House wife Other 
When study staff examine me, they are 
careful to check that I am satisfied  
 
 
Agree 158(53.20%) 126(42.42%) 0.8991 
Disagree 7(2.36%) 6(2.02%)  
I have some doubts about the need for this 
study in the community  
 
 
Agree 143(48.15%) 124(41.75%) 0.0388 
Disagree 22(7.41%) 8(2.69%)  
Sometimes study staff use medical words 
without explaining  
 
 
Agree 134(45.12%) 114(38.38%) 0.2346 
Disagree 31(10.44%) 18(6.06%)  
Study staff are too businesslike and 
impersonal toward me  
 
 
Agree 118(39.73%) 92(30.98%) 0.7323 
Disagree 47(15.82%) 40(13.47%)  
Study staff treat me in a friendly and 
courteous manner  
 
 
Agree 144(48.48%) 118(39.73%) 0.5732 
Disagree 21(7.07%) 14(4.71%)  
Study staff sometimes hurry too much 
during the study visits  
 
 
Agree 132(44.44%) 107(36.03%) 0.8188 
Disagree 33(11.11%) 25(8.42%)  
Study Staff usually spend plenty of time 
with me  
 
 
Agree 152(51.18%) 124(41.75%) 0.5436 
Disagree 13(4.38%) 8(2.69%)  
(continued) 
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Occupation  
  
P value Satisfaction Item Housewife Other 
Study staff is good about explaining 
reasons for the research study  
 
 
Agree 160(53.87%) 129(43.43%) 0.6886 
Disagree 5(1.68%) 3(1.01%)  
Study staff sometimes ignore what I tell 
them  
 
 
Agree 145(48.82%) 122(41.08%) 0.1965 
Disagree 20(6.73%) 10(3.37%)  
I feel confident that I can complete all 
study visits without spending too much 
money   
 
 
Agree 162(54.55%) 132(44.44%) 0.1195 
Disagree 3(1.01%) 0(0.00%)  
I have to spend more than I can afford to 
be part of this study  
 
 
Agree 161(54.21%) 127(42.76%) 0.4957 
Disagree 4(1.35%) 5(1.68%)  
The study visit hours are convenient for 
me  
 
 
Agree 160(53.87%) 131(44.11%) 0.1666 
Disagree 5(1.68%) 1(0.34%)  
I have easy access to study staff when I 
need to  
 
 
Agree 154(51.85%) 124(41.75%) 0.8320 
Disagree 11(3.70%) 8(2.69%)  
I find it hard to reach the study staff right 
away when I need to  
 
 
Agree 151(50.84%) 124(41.75%) 0.4280 
Disagree 14(4.71%) 8(2.69%)  
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Analysis of the Informed Consent Comprehension Questionnaire 
In the informed consent comprehension questionnaire, the questions focus on the 
required components of the informed consent form which are an introduction, an 
explanation of study procedures, risks and benefits, withdrawal, voluntary research 
participation and confidentiality.  
Only 3.37% of the participants answered correctly that the reason their child was 
asked to attend the clinic so that their baby can participate in a research study. For the 
purpose of the study, 65.32% correctly identified it as being to find out the amount of TB 
disease and TB infection in children. The reason of the study, 64.98% correctly answered 
that the research staff wanted their child enrolled in the study so they could test them for 
TB and HIV. For the study duration, 83.16% correctly answered that they were expected 
to participate in the study is 2 years. Risks of study, 14.14% correctly identified the most 
common risk of being collected from their child as blistering or an open sore. Only 
2.02% correctly answered that there are no immediate benefits available for the 
participants and their children to participate in the TB study. In terms of the ability to 
withdraw, 61.62% answered correctly that their child or they would suffer no loss at all if 
they chose to leave the study. As for confidentiality, 30.30% answered correctly that 
number and codes will be used to link the child to the samples. In terms of their own 
opinion on the reason for enrolling their child in the research study, 14.48% answered 
correctly that it is because they wanted to help the doctors learn more about TB. For 
voluntary research participation, 36.70% correctly answered that they can withdraw their 
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child at any time they wished. Table 9 contains the % correct responses and the number 
(n) of participants who chose the correct answer on all questions. 
Table 9 
Management of Data on Overall Informed Consent 
Informed Consent Question % correct  n=297 
 1. What was the reason you were asked to attend the 
clinic?  3.37 10 
 2. What is the purpose of the research study? 65.99 196 
 3. Why does the research staff want to enroll my baby into 
the research study? 65.66 195 
 4. What is the total amount of time my baby will be 
expected to participate in the study? 83.50 248 
 5. What is the most common risk involved when blood had 
been collected from my baby? 14.14 42 
 6. What benefits are available to me and my baby for 
participating in the study? 2.02 6 
 7. What if I didn't want my baby to participate in this 
study, I could withdraw  61.62 183 
 8. How will my baby's personal details be kept secret? 30.64 91 
 9. Why did I agree to enroll my child in this study? 14.48 43 
 10. How long do I have to keep participating in the study? 36.36 108 
 
The results of the some of the questions showed evidence of therapeutic misconception 
which is the notion research participants will confuse their participation into the research 
study as obtaining treatment. These were shown in graphical form in Figures 6-8. 
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Figure 6. Percent selected on reason for attending the clinic 
Erroneously, 74.75% chose that they were attending the clinic so that their baby can 
receive routine health care. The question on benefits also shows evidence of therapeutic 
misconception as shown in Figure 7. 
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Figure 7. Percent selected on benefits for participating in the study 
The same evidence of therapeutic misconception appeared on the selected benefits 
available to participants and their babies for participating in the study as shown in Figure 
7. Of those, 30.30% thought their child will be protected against TB in participating in 
the study, and 28.96% thought that their child will receive better treatment at the clinic 
while only 2.02% correctly thought that there are no immediate benefits. 
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Figure 8. Percent selected on reasons for agreeing to be enroll their child in the study 
The idea that there is an imbalance of power between the research participants 
and the study staff was also reflected in the results as shown in Figure 8. A number 
participants (25.59%) thought they had to stay in the study until it was completed. As for 
the right to withdrawal, 30.30% thought they could only withdraw if given permission 
and only 36.70% thought they could withdraw at any time if they wished. Table 10 shows 
all the answers on the informed consent questionnaire including the number of 
participants who chose particular answers. 
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Table 10 
All Answers on Informed Consent 
 Informed Consent Question  N (% selected)
 1. What was the reason you were asked to attend the clinic?   
So my baby can participate in a research study 10 (3.37%) 
So my baby can receive expert treatment 38 (12.79%) 
So my baby can receive routine health care 222 (74.75%) 
Unknown 4 (1.35%) 
Other 23 (7.74%) 
 2. What is the purpose of the research study?  
To find out the amount of TB disease and TB infection in children 194 (65.32%) 
To find out if my child was vaccinated for TB 14 (4.71%) 
To find out if BCG vaccination works in children 29 (9.76%) 
Unknown 16 (5.39%) 
Other 44 (14.81%) 
 3. Why does the research staff want to enroll my baby into the research 
study?  
So they can test my child for TB or HIV 193 (64.98%) 
So they can collect blood from my child 2 (0.67%) 
So they can inject my baby with BCG 32 (10.77%) 
Unknown 17 (5.72%) 
Other 53 (17.85%) 
 4. What is the total amount of time my baby will be expected to 
participate in the study?  
0:00:02 18 (6.06%) 
0:00:03 247 (83.16%) 
0:00:04 7 (2.36%) 
0:00:05 25 (8.42%) 
 5. What is the most common risk involved when blood had been collected 
from my baby?  
My child may suffer from blistering or an open sore from the TB skin test 42 (14.14%) 
My child can become infected with TB 26 (8.75%) 
My child can lose blood 54 (18.18%) 
Unknown 81 (27.27%) 
Other 94 (31.65%) 
(continued) 
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 Informed Consent Question N (% selected)
 6. What benefits are available to me and my baby for participating in the 
study?  
My child will be protected against TB 90 (30.30%) 
There are no immediate benefits 6 (2.02%) 
My child and I will get better treatment at clinics 86 (28.96%) 
Unknown 4 (1.35%) 
Other 111 (37.37%) 
 7. What if I didn't want my baby to participate in this study, I could 
withdraw   
My child and I would suffer no loss at all 183 (61.62%) 
My child and I will be treated differently by research and clinic staff 54 (18.18%) 
My child and I would be denied access to health services at this clinic 35 (11.78%) 
Unknown 11 (3.70%) 
Other 14 (4.71%) 
 8. How will my baby's personal details will be kept secret?  
Numbers and codes will be used to keep from linking your child to the 
samples 
90 (30.30%) 
Highly trained research staff will keep information secret 73 (24.58%) 
Clinic staff will be sure not to give information to the research staff 55 (18.52%) 
Unknown 49 (16.50%) 
Other 30 (10.10%) 
  
 9. Why did I agreed to enroll my child in this study?  
Because I want doctors to help learn more about TB 43 (14.48%) 
So my child might get better treatment 201 (67.68%) 
So my family might benefit from other health services 17 (5.72%) 
Unknown 2 (0.67%) 
Other 34 (11.45%) 
 10. How long do I have to keep participating in the study?  
Until the study is completed 76 (25.59%) 
I can withdraw at any time if I wish 109 (36.70%) 
I can only withdraw if the clinic staff give me permission 90 (30.30%) 
Unknown 1 (0.34%) 
Other 21 (7.07%) 
 
The informed consent data were examined in terms of the elements of informed consent 
as shown in Figure 9. 
  
96
 
 
Figure 9. Percent answered correctly for each element of informed consent 
 
The categories where most participants had correct answers were the following: 
perceived risk of withdrawal (61.62%), study duration (83.5%), procedure (65.66%), and 
purpose of the study (65.99%). In the categories, most answers were incorrect and only 
the following percent was answered correctly: voluntary participation (14.48%), 
confidentiality (30.64%), benefits (2.02%), risk (14.14%), and general information 
(3.37%). The benefits question had the least correct answers. In looking for correlation 
between the participants’ duration in the study and the percent questions answered 
correctly, chi square analysis was performed for each informed consent comprehension 
question and resulted as show in Table 11. P-values were high in the analysis which 
suggests that there may not be a significant difference between the two groups (those had 
been in the study for < 2 yrs vs. ≥ 2 yrs) in their responses. 
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Table 11 
Chi Square Analysis of % Correct Informed Consent Questions and Duration in the Study 
 % correct Duration in the study   
P 
value Informed Consent Questions < 2 yrs ≥ 2 yrs 
 1. What was the reason you were asked to attend the clinic?     
CORRECT 9(3.03%) 1(0.34%) 0.7501 
NOT CORRECT 266(89.56%) 21(7.07%)  
 2. What is the purpose of the research study?    
CORRECT 177(59.60%) 17(5.72%) 0.2209 
NOT CORRECT 98(33.00%) 5(1.68%)  
 3. Why does the research staff want to enroll my baby into the 
research study?   
 
CORRECT 178(59.93%) 15(5.05%) 0.7438 
NOT CORRECT 97(32.66%) 7(2.36%)  
 4. What is the total amount of time my baby will be expected to 
participate in the study?   
 
CORRECT 226(76.09%) 21(7.07%) 0.1094 
NOT CORRECT 49(16.50%) 1(0.34%)  
 5. What is the most common risk involved when blood had been 
collected from my baby?   
 
CORRECT 41(13.80%) 1(0.34%) 0.1795 
NOT CORRECT 234(78.79%) 21(7.07%)  
 6. What benefits are available to me and my baby for participating 
in the study?   
 
CORRECT 6(2.02%) 0(0.00%) 0.4840 
NOT CORRECT 269(90.57%) 22(7.41%)  
 7. What if I didn't want my baby to participate in this study, I 
could withdraw    
 
CORRECT 168(56.57%) 15(5.05%) 0.5105 
NOT CORRECT 107(36.03%) 7(2.36%)  
 8. How will my baby's personal details will be kept secret?    
CORRECT 82(27.61%) 8(2.69%) 0.5203 
NOT CORRECT 193(64.98%) 14(4.71%)  
 9. Why did I agree to enroll my child in this study?    
CORRECT 38(12.79%) 5(1.68%) 0.2532 
NOT CORRECT 237(79.80%) 17(5.72%)  
 10. How long do I have to keep participating in the study?    
CORRECT 105(35.35%) 4(1.35%) 0.0611 
NOT CORRECT 170(57.24%) 18(6.06%)  
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In assessing for correlation between the experience of the staff administering 
consent and the percent questions answered correctly, chi square analysis was performed 
for each informed consent comprehension question and resulted as show in Table 12. P-
values were high in the analysis which suggests that there may not be a significant 
difference between the two groups (those who were consented by staff with less than 5 
years’ experience vs. more than or equal to 5 years of experience) in their responses. 
Table 12 
Chi Square Analysis of % Correct Informed Consent Questions and Staff Experience 
 
 % correct Staff experience   
P value Informed Consent Questions < 5 yrs ≥ 5 yrs 
 1. What was the reason you were asked to 
attend the clinic?    
 
CORRECT 5(1.77%) 5(1.77%) 0.6445 
NOT CORRECT 116(41.13%) 156(55.32%)  
 2. What is the purpose of the research 
study?   
 
CORRECT 81(28.72%) 101(35.82%) 0.4646 
NOT CORRECT 40(14.18%) 60(21.28%)  
 3. Why does the research staff want to 
enroll my baby into the research study?   
 
CORRECT 76(26.95%) 104(36.88%) 0.7573 
NOT CORRECT 45(15.96%) 57(20.21%)  
 4. What is the total amount of time my 
baby will be expected to participate in the 
study?   
 
CORRECT 105(37.23%) 130(46.10%) 0.1786 
NOT CORRECT 16(5.67%) 31(10.99%)  
(continued) 
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 % correct       Staff experience 
Informed Consent Questions < 5 yrs ≥ 5 yrs P value 
 5. What is the most common risk 
involved when blood had been collected 
from my baby?   
 
CORRECT 18(6.38%) 20(7.09%) 0.5503 
NOT CORRECT 103(36.52%) 141(50.00%)  
 6. What benefits are available to me and 
my baby for participating in the study?   
 
CORRECT 5(1.77%) 1(0.35%) 0.0431 
NOT CORRECT 116(41.13%) 160(56.74%)  
 7. What if I didn't want my baby to 
participate in this study, I could withdraw    
 
CORRECT 68(24.11%) 106(37.59%) 0.0993 
NOT CORRECT 53(18.79%) 55(19.50%)  
 8. How will my baby's personal details be 
kept secret?   
 
CORRECT 36(12.77%) 46(16.31%) 0.8289 
NOT CORRECT 85(30.14%) 115(40.78%)  
 9. Why did I agreed to enroll my child in 
this study?   
 
CORRECT 22(7.80%) 19(6.74%) 0.1325 
NOT CORRECT 99(35.11%) 142(50.35%)  
 10. How long do I have to keep 
participating in the study?   
 
CORRECT 46(16.31%) 55(19.50%) 0.5040 
NOT CORRECT 75(26.60%) 106(37.59%)  
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Summary of All Results 
 According to the study demographics, all participants were women, the majority 
being less than 35 years of age, housewives with at least a primary level of education and 
they all have been participating in the study for less than 12 months. Research data were 
analyzed to answer the research questions as follows: 
Research Question 1 
Overall, the site’s performance was in line with GCPs and with international 
standards since the site received an excellent score in the GCP checklist and there were 
no major or critical findings. The few minor findings that were observed had no or 
minimal impact on patient safety, data integrity or study outcome. The laboratory was the 
study functional area with the most findings and observations and the area of document 
management had the least number of findings from the GCP checklist. 
Research Question 2 
The historical trend comparing assessments, audits and monitoring activities since 
2008 showed an upward trend in the level of compliance with GCP standards. The site 
showed a great deal of improvement as time went on so to have an excellent audit in the 
last evaluation performed in January 2012. The area of protocols and protocol 
amendments had the most observations and findings throughout the years and the aspects 
of monitoring and personnel & training had the least number of findings and 
observations. As mentioned in Chapter 3, every note of noncompliance or questionable 
alignment with GCP is considered either a finding or an observation. A finding may not 
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necessarily be negative; however, it is a point that ought to be noted by the research site. 
The difference between a finding and an observation is described in Chapter 3. 
Research Question 3 
The majority of study participants were contented in all aspects measuring 
satisfaction with their participation in the study. A high percentage of participants were 
satisfied in terms of participant-study staff interaction, informativeness of the materials 
provided during the study, physical infrastructure of the facilities, convenience, and 
accessibility of research study facilities, financial factors, procedures and tests, and 
flexibility of timing of procedures. Chi square analysis comparing the satisfaction level 
between different age groups (≤25 vs. > 25 years of age), between different levels of 
education (none vs. some education) and between different occupations (housewives vs. 
other) revealed no significant differences in the level of satisfaction. 
Research Question 4 
For informed consent comprehension, the results revealed that the components of 
the informed consent form most understood were related to perceived risk of withdrawal, 
study duration, procedure and purpose. The components that were least understood were 
right to withdrawal, voluntary participation, confidentiality, benefits, risk, and general 
information. The idea of therapeutic misconception resonated in the results since only 
2.02% understood that there were no immediate benefits in participating in the research 
study and the rest thought that they were receiving some type of prophylaxis or treatment 
against TB. Chi square analysis comparing the informed consent comprehension between 
groups of different duration in the study (less than vs. greater than or equal to 2 years), 
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between participants consented by staff of different levels of experience (less than vs. 
greater than or equal to 5 years) revealed no significant difference in the level of 
comprehension. 
In Chapter 5, conclusions and recommendations will be made from the data as 
presented. Discussion on the impact of the findings on the GCP checklist and the trending 
analysis will be deepened. Also, the issues that arose from the data on participant 
satisfaction and informed consent comprehension will be further explored. 
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Chapter 5: Summary, Conclusions, and Recommendations 
Capacity building activities for the conduct of clinical research studies is 
occurring in developing countries. In Africa, the intent of building this capacity is to 
promote health research in the continent and to facilitate means for the highest standards 
of scientific research to ensure long-term health and wellbeing of its population. It is 
important to evaluate the impact of the capacity building activities so as to allow the 
researchers to learn from their own experiences, to generate evidence of transparency and 
accountability, as well as to reveal mistakes and offer paths for improvement.  
This research was an evaluation study of capacity-building efforts for the conduct 
of clinical research in Kisumu, Kenya. It consisted of an assessment of the research site’s 
compliance with GCP in performing an infant TB epidemiology study, an evaluation of 
the level of comprehension informed consent form and process as well as a measure of 
the level of satisfaction of the parents of the TB epidemiology study with their experience 
in the research. The study also involved a review and analysis of audits and monitoring 
findings from the site since 2008. 
Summary of the Study 
The study was conducted in two parts. First, the quality assurance aspect of the 
site and its conduct of an infant TB epidemiology study were assessed. Then, the 297 
participants (mothers of the infants enrolled in the epidemiology) were involved in 
collecting data regarding their level of comprehension of the informed consent form as 
well as their level of satisfaction with the study procedures and study staff. 
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The mean age of the participants was 26.2 years of age and the median age was 
25. The entire study sample was composed of females. More than 87% of them were 35 
years old or younger and more than half (55.56%) were housewives, meaning that they 
did not have an occupation outside the home. About 88% of the participants had either 
none or only a primary school education and all of them (100%) had participated in the 
study. 
According to the assessment through the GCP checklist, the site and the conduct 
of study were near excellent as they received a score of 94.24%. The quality assurance 
that was put in place functions well and the components of GCP compliance were 
satisfied. Although the assessment brought forth some minor findings, the level of 
compliance with the various components of GCP (i.e., document management, personnel 
and training, data management, protocol adherence, monitoring, CAPA, and laboratory) 
was satisfactory. 
In the trending analysis that followed the GCP checklist audit, the study had made 
progress in terms of their compliance with GCP since their first audit in 2008. Overall, 
there was improvement throughout the areas of GCP. The number of observations, which 
are notes of noncompliance or questionable alignment with GCPs, decreased from 48 in 
2008 to 12 in 2012 (73% decrease).  
In general, the level of satisfaction of participants was high in all areas measured 
in terms of participant-study staff interaction, informativeness of the materials provided 
during the study, physical infrastructure of the facilities, convenience and accessibility of 
research study facilities, financial factors, procedures and tests, and flexibility of timing 
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of procedures. In correlating the level of satisfaction among different age groups (≤25 vs. 
> 25 years of age), different occupation (housewives vs. other), different level of 
education (none vs. some education), no statistically significant difference was revealed.  
For the level of comprehension of the informed consent forms, the aspects of the 
informed consent form that were most understood were the ones concerning perceived 
risk of withdrawal, study duration, procedure, and purpose. Other aspects such as right to 
withdrawal, voluntary participation, confidentiality, benefits, risk, and general 
information were least understood. A correlation between groups of different duration in 
the study (less than vs. greater than or equal to 2 years), between participants consented 
by staff of different levels of experience (less than vs. greater than or equal to 5 years) 
showed that these groups did not significantly differ in their level of comprehension.  
Conclusions and Discussions 
Based the demographics of this study, the majority of the women were younger 
than 35: housewives with at least a primary level of education are the expected 
population for guardians of infants enrolled in an epidemiological study in the 
geographical area where study was conducted (Aeras, 2008). Since mothers are expected 
to be the ones taking their children to seek healthcare, the sample population for this 
evaluation study was exclusively female. Mothers are expected to be young and of 
childbearing age since the children enrolled in the epidemiology study were 2 years old 
and younger. As for the level of education, it was also as expected for a female 
population in eastern Africa. 
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 The conclusions for this study are grouped according to the research questions 
that were posed in the study design. 
Research Question 1 
The KEMRI/CDC site in Kisumu, Kenya, conducting the infant TB epidemiology 
study can be deemed a suitable site in terms of performance. The assessment, through a 
GCP checklist, revealed an excellent score of 94.24%. The site had a few minor findings 
mainly related to the laboratory (46%), data management (23%), personnel and training 
(15%), monitoring (8%), and protocol and protocol amendments (8%). The minor 
findings are not consequential in terms of their impact on the integrity of the data, nor do 
they compromise the research participants’ safety of the respect for their autonomy 
(FDA, 2007). Minor findings are those issues that represent a departure from the protocol 
or a stated ICH GCP guideline, regulation or SOP, with no or minimal impact on patient 
safety, data integrity or study outcome. They represent a divergence or noncompliance 
from the protocol or the procedures originally set for the conduct of the study. No major 
or critical findings were noted. Had they been present, itwould have signified major 
deficiencies with the site performance in terms of GCP compliance. Hence, this site can 
be considered more than adequate for conducting clinical research involving human 
participants.  
 This site functions in accordance to GCP as described in the guidance document 
from the ICH of Technical Requirements for Registration of Pharmaceuticals for Human 
Use. In this document, the ICH (2010) guidelines specify that it is required for a sponsor 
conducting clinical research to “implement and maintain a quality assurance and quality 
  
107
control system for to ensure that the trials are conducted and data are generated in 
compliance with the protocol, GCP and the applicable regulatory requirements” (p. 13). 
With such an excellent score in the GCP checklist, the site is showing a high level of 
compliance with GCPs which leads to the conclusion that the site is committed to 
ensuring that they “play by the rules” and they do not take regulations and expectations 
of the guidelines lightly. According to the high level of GCP compliance observed at this 
site, the staff appreciates how failure to comply with the regulations and guidelines for 
clinical research can be hazardous to their success in terms of the data they generate and 
the ethics of conducting research with human participants. 
 The quality management system that the site has implemented facilitates their 
compliance with GCP Their quality assurance includes SOPs, a group of staff dedicated 
to QA, a tight system of documentation, trained staff, and a quality control system that 
anticipates issues and ensures that they are resolved in a manner that is least 
compromising to the study being conducted. This systemic approach to compliance 
reduces mistakes and minimizes nonconformance to specifications, standards, and 
expectations in the most cost effective and efficient manner. 
The few minor findings that were revealed by the assessment are also an 
indication that the site is continuously operating and that mistakes are inevitable.  
Research Question 2 
It should be noted that although the research questions prescribes to analyze the 
historical trend of the site quality indicators for the past 2 years, it was decided to 
consider an assessment from 2008 as this document was the first inspection conducted to 
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assess compliance with GCP standards. Since the data collection of this dissertation was 
intended to be initiated in 2010, the 2008 report was originally meant to be taken into 
consideration during the data collection. Although data collection for trending analysis 
was initiated in January 2012, the analysis was extended to the 2008 report so to enhance 
the trend observed at the site. 
 Over all, according to the trending analysis, there was an upward trend in terms of 
compliance with GCP standards since the first assessment in 2008. The areas being 
observed, as indicated by GCP guidelines, were protocol adherence, laboratory, data 
management, document management, personnel and training, as well as monitoring. 
Since 2008, the site has made improvement in terms of total number of findings and 
observations with a decrease of 73%. Protocol adherence is the area most improved as it 
decreased the number of observation and findings from 21 in 2008 to one in 2012 (Table 
9). All findings and observations are issues identified for noncompliance or questionable 
alignment with GCPs. 
 Before and during the site implementation of the infant TB data, training activities 
were conducted at the site. These training events were aiming to develop a cadre of 
professionals capable of conducting clinical research studies compliant with ethical and 
regulatory standards. The training was delivered in different forms such as face-to-face 
training, e-learning, “learning by doing” activities, and mentoring. The topics covered 
were GCP, GLP, research ethics, epidemiology, biostatistics, infectious disease, and other 
areas related to the conduct of community-based TB vaccine research in accordance with 
international standards. The impact of this training was revealed through the upward 
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trending in improvements with GCP compliance throughout the years. The decrease 
number of observations showed that level of site performance is increasing.  
The higher levels of GCP compliance may translate to the improvement in the 
quality of the TB epidemiology study in terms of data integrity and protection of the 
rights of the study participants. Since the site is now conducting clinical trials intended 
for submission to the U.S. FDA, they are susceptible to an inspection by a stringent 
regulatory authority. With this level of compliance, it is likely that the preparation for 
such an inspection would be minimal since the systems and the ground work has been 
established to promote success if such scrutiny was to occur at the site (Axson, 2007).   
In a study conducted by the Tuberculosis Trials Consortium (TBTC, 2007), an 
evaluation of the QA through the use of quality indicators was performed. As in this 
dissertation study,  TBTC found that collecting quality assurance data throughout a study 
performance promoted the improvement in terms of quality assurance. In their study, the 
TBTC collected performance data real-time and compared results throughout the 28 sites 
involved in their study. Results from their frequent assessments were fed into a corrective 
action plan that allowed the site to learn and improve as time went by (Sandman et al., 
2006). The TBTC study supports the idea that continuous QA checks improve a site’s 
compliance with GCP and other standards. This improvement aspect is also evident in the 
Kenya site evaluated in this dissertation as, through time, a number of QA checks have 
propelled the site to an excellent level of compliance. As in the TBTC study, the findings 
and observations resulting from each quality check were subjected to a corrective action 
that allowed for mistakes to be corrected and the correct path to be established. 
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Research Question 3 
As shown in Figure 2, the assessment of participant’s satisfaction was based on a 
multifactorial approach that took into account various aspects that impact how content the 
participant feels with her involvement in the study. The factors are related to the 
participants’ characteristics such as perceived efficacy, the various studies’ aspects such 
as enrollment process, documentation to be read, and study procedures. The clinical 
setting itself (i.e., transportation, scheduling) was also expected to play a role in the part 
in the level the satisfaction. All of these aspects fed into the relationship between the 
research participants and research staff, which ultimately led to the degree of 
participants’ satisfaction.  
 In this evaluation study, the level of satisfaction was consistently high throughout 
the various elements of satisfaction that were assessed. The majority of participants (no 
less than 70%) were always satisfied in terms of general satisfaction, technical quality, 
interpersonal manners, communication, financial aspects, accessibility, and convenience 
(Table 5). In a study conducted in 25 countries around the globe, Lavoski et al. (2009) 
sought research participants’ opinions in regards to the medical and nonmedical benefits 
of participating in an HIV treatment study. As in this evaluation study, the participants 
themselves were given the opportunity to express their contentment with various aspects 
of the study. Lavoski et al. (2009) found that the results of their study were valuable in 
helping the researchers understand how to better design studies with the community’s 
best interests in mind. 
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Chi square analysis comparing the satisfaction level between different age groups 
(≤25 vs. > 25 years of age), between different levels of education (none vs. some 
education), and between different occupations (housewives vs. other) revealed no 
significant difference in the level of satisfaction between the groups compared as shown 
by the high p values. Specifically, the data on each satisfaction questions were analyzed 
to see if, for example in the different age groups, the younger group had a statistically 
significant different level of satisfaction than the older age group. The high p values lead 
to the conclusion that all participants were satisfied in the same manner regardless of age, 
education level, or occupation. In a study conducted by Hunter et al. (2009), patient 
satisfaction in retail health clinics was assessed and the level of satisfaction was 
compared in terms of ethnicity and socioeconomic status. Hunter et al. also concluded 
that the level of satisfaction was “homogeneous” throughout the groups. It should be 
noted that the study population in the Hunter et al. study is different from those in this 
evaluation since the Hunter et al. study was conducted in a community in Arizona in the 
United States as opposed to the rural Kenyan population of this evaluation study. 
However, it may be possible that satisfaction in the health arena may also be consistent as 
the respondents are dealing with a valued human need which is the need for good health. 
Research Question 4 
 Ethical considerations are the cornerstone of clinical research involving human 
participants. It is essential to respect the research volunteer’s right to autonomy. Hence, 
the process of informed consent comprises of not only providing information on the 
research but also comprehension of the various elements of study (purpose, risk, benefits, 
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procedures, and treatment) and that of the informed consent process itself 
(confidentiality, voluntariness of participation, and such). In this evaluation study, 
questions were posed in regards to the informed consent form and process and the correct 
answer is considered the answer that I expected. The most understood aspects of the 
informed consent process were related to perceived risk of withdrawal, study duration, 
procedure, and purpose (Table 10). The least understood aspects of the informed consent 
process were related to right to withdrawal, voluntary participation, confidentiality, 
benefits, risk, and general information (Table 10).  
Minnies et al.  et al. (2008) analyzed recall and understanding of informed 
consent in a mother with children enrolled in a TB epidemiology study in South Africa. 
Due to the difference in study design between the Minnies et al.  et al. study and this 
evaluation study, a direct comparison could not be made. However, some of the results 
were able to be compared due to the similarity in some of the questions that were posed. 
For example, in the Minnies et al.  et al. study, 51.3% answered correctly on the 
questions regarding the benefits of study participation (Minnies et al.  et al., 2008) while 
only 2.02 % correctly answer a similar question in this evaluation study. This difference 
may be inherent to the nature of the study population. In the Minnies et al.  et al. study, 
the demographics were different as the majority (76.7%) at least reached secondary 
education (Minnies et al., 2008), while in the current evaluation study only 10.44 % 
reached the same level of education (Table 3). There were also divergent results between 
this evaluation and the Minnies et al. study in regards to risks of being involved in the 
study. In the Minnies et al. study, 79.2% answered correctly in regards to the risk of study 
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participation (Minnies et al., 2008) while, in this evaluation study, only 14.14% answered 
a similar question correctly. The difference in the level of education may explain the 
difference in the level of comprehension results between the two studies. Minnies et al. 
also mentioned that his results may have been influenced by the fact that the population 
in South Africa may have a heightened aware of their health rights in regards to access to 
healthcare, freedom of choice and freedom from harm. This high level of awareness may 
be due the abusive past that the people of South Africa endured such as Apartheid. 
Having experienced such harsh historical conditions may have made the South Africa 
population more alert when their rights were concerned. It is thus possible that the 
women in South Africa were paying more attention and were more analytical during the 
informed consent process so to protect themselves from any potential abuse.  
The notion of therapeutic misconception occurs in clinical research when research 
participants misconstrue the study research procedures as provision of healthcare or 
treatment for the condition being studied. In other words, the research participants failed 
to understand that the procedures of the research are not particularly tailored to treat their 
own individual conditions and that due to research characteristics such as randomization; 
they may not automatically obtain treatment from participating in a research study. 
Falagas et al. (2009) conducted a systematic literature review in order to evaluate the 
“degree of patient’s understanding of several aspects of the informed consent process for 
surgery and clinical research (p. 198). Falagas et al found that in one of the studies 
reviewed, as many as 85% of research participants gave the impression of expecting to be 
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fully treated as a result of participating in the trial. The notion of therapeutic 
misconception was apparent.  
In this evaluation study, the idea of therapeutic misconception started emerging in 
the question regarding the reason for being asked to attend the clinic. Only 3.37% of the 
participants answered correctly that they were asked to attend the clinic so their baby 
could participate in a research study. Instead, 74.75% incorrectly answered that they were 
asked to attend the clinic so that their baby can receive routine care (Figure 6). The 
notion of therapeutic misconception continued to appear in later questions. When the 
participants were asked about the benefits available to them and their baby for 
participating in the study, only 2.02% correctly answered that there were no immediate 
benefits while 30.30% and 28.96% answered that their child will be protected against TB 
and that their child will receive better treatment against TB, respectively (Figure 7). 
Finally, the perception of therapeutic misconception was still apparent when, as shown in 
Figure 8, only 14.48% answered correctly they wanted to help doctors learn more about 
TB while 67.68% answered that that they thought their child would get better treatment. 
The results from these 3 questions tend to follow the same theme where the mothers of 
the infants participating in the TB study are misconceiving their child’s participation in 
the TB epidemiology study as in means for obtaining treatment from the clinic. After an 
adequate informed consent process, the study participants are expected to be able to 
recognize that they have the right to discontinue their involvement in the study whenever 
they wish without worrying about losing any benefits. This point is one of the basic 
elements of the informed consent in research with human participants. Since most women 
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did not answer the “right to withdrawal” question correctly, there was likely a disconnect 
in their understanding of their commitment to the study. The same thoughts may apply 
for the reasons for the incorrect responses in the “voluntary participation” questions. 
Respecting the participant’s autonomy is rooted in her voluntary participation in the 
study. It is critical that the participant understand that she is participating in the study out 
of her own volition. The large number of incorrect answers of these questions suggests 
that the participants did not completely grasp the notions imparted during the informed 
consent process.  
The results of this evaluation are congruent with those found by Falagas et al. in 
terms of the evidence that the research participants seem to believe that they will received 
better healthcare or treatment for taking part in a research study. This notion is dangerous 
as it shows that clinical care may not always be distinguished from clinical research. This 
confusion may due to the fact that research is being conducted in clinical settings 
although it is pure an academic activity. The participants may be requested to participate 
in research by the same medical staff that provides them with their usual healthcare. It is 
thus the responsibility of research staff to ensure that the research participants are aware 
that the intentions of clinical research are purely investigative and that they impose 
discomforts or risks for harm that are necessarily not rewarded by personal diagnostic or 
therapeutic benefits such as in clinical care.  
An attempt was made to differentiate the level of comprehension between 
different groups in the participant’s population. Chi square analyses comparing the 
informed consent comprehension between groups of different duration in the study (less 
  
116
than vs. greater than or equal to 2 years), between participants consented by staff of 
different levels of experience (less than vs. greater than or equal to 5 years) revealed no 
significant difference in the level of comprehension as p-values were high from the 
analysis. It is possible that, as in the participant satisfaction results, the level of informed 
consent comprehension was homogeneous between those participants who had remained 
in the study for less than 2 years and those that had participated in the for 2 years or 
more.  
Recommendations 
Capacity building for health programs and research is currently conducted by 
various organizations and institutions in Africa. While existing efforts are recognized, it 
is important to highlight that there is still a need for the promotion of the creation of self-
sustaining institutions of excellence capable of initiating and carrying out high quality 
health research in Africa. The capacity that is being built should be able to translate 
research products into policy and practice through better integrated approaches of 
capacity building at individual, institutional and system levels. Opportunities for capacity 
building should focus on opening up discussions avenues for African researchers to share 
ideas among themselves and around the globe. The discussions about capacity building 
for heath research in Africa should be led by African researchers as they are most in tune 
with their own needs. At the same time any capacity building projects should pull in 
African national governments and civil societies (such as nongovernmental organizations 
and community-based organizations) in order to foster an environment that is conducive 
to sustainable health research growth. 
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The participants had a high level of satisfaction in regards to their involvement in 
TB epidemiology study. A follow-up qualitative study could be conducted to address the 
specific needs of the participants. Probing questions would be asked about the informed 
consent process in terms of how they understood each element of informed consent such 
as goal and purpose of the study, confidentiality, voluntary participation and right to 
withdrawal. The results of such a study may be useful in formulating informed consent 
documents so to make them comprehensible for this particular population. The next study 
should focus on the participants’ experiences and expectations using a focus group 
format. This methodology will allow for conversation among participants which will 
elicit information that shows the community’s perspective on participation in research 
studies. This follow-up study could also include individuals in the community that have 
never participated in research so to compare their point of view to those who are veteran 
research participants. 
The notion of therapeutic misconception was recurring throughout the results of 
informed consent comprehension portion of this study. It is important to highlight the fact 
that recruiting research participants in clinical settings lends to confusing the goals of 
clinical research (which are to investigate different products or different ideas) to those of 
clinical care (which are to treat and provide care for health of individuals). In developing 
countries, the lines between clinical research and clinical practice can be blurred. Future 
studies should focus on understanding how misplaced trust of research participants can 
affect their voluntariness of participation in research studies and how this can affect the 
respect of participants’ rights.   
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Implications for Social Change 
One of the most significant social changes impacted by this evaluation study is 
related to the inefficiency of the informed consent process as it is currently being handled 
at the Kenya site.  Although this site is perform successfully in terms of GCP audit, trend 
analysis and participant satisfaction, the informed consent comprehension data suggests 
that research participants do not fully understand the benefits of the study.  This issue is 
not unique to the Kisumu research site.  The notion of therapeutic misconception is 
common in Africa (Oduro et al., 2008).  This evaluation study provides additional 
evidence and confirms that the issue should not be neglected.  This data ought to lead the 
global research community in a quest for better methods of ensuring genuine informed 
consent in populations of developing countries.  In these regions of the world, cultural 
and language obstacles may prohibit adequate comprehension of informed consent when 
administered as indicated in the current international guidelines and regulations. 
It is doubtful that the consent provided by the research participants at the Kisimu 
site is truly informed and genuine.  For this site, the informed consent administration is 
being conducted as a single event while it should take on the form of a process which 
starts at the time of recruitment and systematically continues for the duration of the study 
up to study close-out.  Such a reiterative process will lessen the risk of misunderstanding 
and enhance the chances of genuine and true informed consent. 
As the influx of clinical research studies in Africa increases, the need for high 
quality research sites becomes urgent. This evaluation study contributes to the growing 
body of knowledge showing that applying stringent quality management systems, in 
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resource limited environments, does in fact result in facilities, staff and an environment 
that is capable of conducting clinical research studies that comply with international 
standards such as GCP. Although the Kisumu site exists in an environment that does not 
benefit from resources of similar sites in the developed world, the Kisumu site was able 
to show improvement in quality assurance of clinical research which compares to 
experienced sites in affluent countries such as the United States of America. 
Looking at the quality of clinical research through the eyes of participants 
provides for an unexplored approach for quality improvement. Research participants can 
take an active role in the conduct of research. Their opinion can be a determinant factor 
in how the study is conducted as opposed to merely being passive participants used solely 
for data collection. Giving the participants an active role adds to the respect for their 
dignity, confidence in the intent of researchers and that of the study itself.  
The African continent will only be able to address its population’s health 
problems once strong health research systems are in place. The Kisumu clinical research 
site is an example of a successful capacity building effort for clinical research in a 
resource limited environment. This site was able to capitalize on investments by 
upholding leadership, human and physical infrastructure, ethical practices, as well as 
relationships between the research staff and study participants. Nevertheless, there are 
multiple other existing and potential sites that will only benefit from the same 
investments and successes when capacity building efforts are planned with QA systems, 
community involvement, as well as political will of local governments. 
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Summary 
Investing in capacity building for health research in Africa can be beneficial as 
shown in the Kisimu site in Kenya.  This site is conducting clinical research with the 
same stringency as any high performing research site in affluent countries.  This success 
can be attributed to the quality management systems implemented.  The participants 
involved in the TB epidemiology study are content with their involvement in the study.  
Requiring the participants’ opinion adds to quality improvement of the research study and 
of the site as a whole.  Additional studies may be conducted to further the understanding 
of participants in order to determine how to best ensure continuity of that satisfaction.  
Although the study participants understood some aspects of informed consent, the 
assessment pointed to the possibility of therapeutic misconception being present in the 
study population.  The confusion between clinical research and clinical care ought to be 
researched further in order to best address the problem. Social change was effected in this 
study through the self-reliance that the site possesses now as well as through the research 
participants’ confidence for their involvement in the study. 
  
121
References 
Aeras Global TB Vaccine Foundation. (2010). Retrieved from www.aeras.org  
Aeras (2008). A prospective epidemiological cohort study to evaluate the incidence of 
tuberculosis in infants in Western Kenya. Citation form unpublished organization 
study protocol document.  
Axson, D. (2007). Best practices in planning and performance management: from data to 
decisions. Wiley, 2 ed. Hoboken, NJ. 
Melnick, A., Ek, S. A., & Fazio, M. J. (2005). Finishing high school without trying. Erie, PA: 
Presque Isle. 
Biesma, R., Brugha, R., Harmer, A., Walsh, A., Spicer, N. & Walt, G.  2009). The effects of 
global health initiatives on country health systems: a review of the evidence from 
HIV/AIDS control. Health Policy and Planning 2009, 24, 239–252. 
doi:10.1093/heapol/czp025.  
Bhutta, Z. (2004). Beyond informed consent. Bulletin of the World Health Organization, 
82(10), 771-A. Retrieved from Academic Search Complete database    
Bohaychuk, W., & Ball, G.(1991) “Conducting GCP-compliant clinical research”.: John 
Wiley & Sons. New York, NY 
Bowera, P., King, M., Nazareth, I., Lampe, F., & Sibbald, B. (2005). Patient preferences 
in randomised controlled trials: Conceptual framework and implications for 
research. Social Science & Medicine, 61(3), 685-695. 
doi:10.1016/j.socscimed.2004.12.010. 
  
122
Centers for Disease Control (2010). CDC activities in Kenya. 
http://www.cdc.gov/malaria/malaria_worldwide/cdc_activities/kenya.html. 
Retrieved March day, 2010. 
Clason D., & Dormody T (1993). Analyzing data measured by individual Likert-yype 
items. Journal of Agricultural Education, 35(4), 31-35.  
Cutts F, Enwere G, Zaman S., & Yallop F (2006). Operational challenges in large clinical 
trials: examples and lessons learned from the Gambia Pneumococcal Vaccine 
Trial. PLoS Clinical Trials. e16:1-4.  
Doherty, W. (2000). Family science and family citizenship: toward a model of 
community partnership with families. Family Relations. 49, 319-325. 
Dongbao, Y., Souteyrand, Y., Banda, M., Kaufman, J., & Perriëns, J. (2008). Investment 
in HIV/AIDS programs: Does it help strengthen health systems in developing 
countries?. Globalization & Health, 41-10. doi:10.1186/1744-8603-4-8 
Durand-Zaleski, S., Alberti, C., Durieux, P., Duval X, Gottot, S., Ravaud, P., Gainotti, S., 
Vincent-Genod, C., Moreau, D. & Amiel, P. (2008). Informed consent in clinical 
research in France: assessment and factors associated with therapeutic 
misconception. J Med Ethics. 34(9):e16. 
Falagas, M., Korbila, I., Giannopoulou, K., Kondilis, B. & Peppas, G. (2009). Informed 
consent: How much and what do patients understand? The American Journal of 
Surgery, 198.  
FDA (2006). Strengthening the regulation of clinical trials and bioresearch monitoring. 
FDA Consumer, 40(6), 35. Retrieved from Academic Search Complete database. 
  
123
FDA (2007). Concept paper: quality in FDA-regulated clinical research. HSP/BIMO 
Workshop 5/10-5/11/07. Food and Drug Administration, U.S.  
Finfgeld, D., Wongvatunyu, S., Conn, V., Grando, V., & Russell, C. (2003). Health belief 
model and reversal theory: a comparative analysis. Journal of Advanced Nursing, 
43(3), 288-297. Retrieved September 30, 2009, doi:10.1046/j.1365-
2648.2003.02712.x 
Gikonyo, C., Bejon, P., Marsh, V., & Molyneux, S. (2008). Taking social relationships 
seriously: Lessons learned from the informed consent practices of a vaccine trial 
on the Kenyan Coast. Social Science & Medicine, 67(5), 708-720. 
doi:10.1016/j.socscimed.2008.02.003 
Glanz, K., Rimer, B.K. & Lewis, F.M. (2002). Health behavior and health education: 
theory, research and practice. Wiley & Sons. San Fransisco, CA 
Global Forum For Health Research (2009). Estimated global R&D financing for 
communicable and noncommunicable diseases. 
http://www.globalforumhealth.org/Media-Publications/Archive-news/Estimated-
global-R-D-financing-for-communicable-and-noncommunicable-diseases.  
Green, L. W., & Kreuter, M. W. (1999). Health promotion planning: an educational and 
ecological approach, 3rd edition. Mayfield. Mountain View, CA: 
Grimes, D., Hubacher, D., Nanda, K., Schulz, K., Moher, D., & Altman, D. (2005). The 
Good Clinical Practice guideline: a bronze standard for clinical research. Lancet, 
366(9480), 172-174. doi:10.1016/S0140-6736(05)66875-4. 
  
124
Hanney, S., & Block, M. (2006). Building health research systems to achieve better 
health. Health Research Policy & Systems, 410-6. doi:10.1186/1478-4505-4-10. 
Humayun, A., Fatima, N., Naqqash, S., Hussain, S., Rasheed, A., Imtiaz H & Imam, S. 
(2008). Patients' perception and actual practice of informed consent, privacy and 
confidentiality in general medical outpatient departments of two tertiary care 
hospitals of Lahore. BMC Med Ethics. 25;9:14. 
Hunter, L., Weber, C., Wall, J., & Morreale, A. (2009). Patient satisfaction with retail 
health clinic care. Journal of the American Academy of Nurse Practitioners, 
21(10), 565-570. http://search.ebscohost.com.ezp.waldenulibrary.org, 
doi:10.1111/j.1745-7599.2009.00447.x 
International Conference on Harmonisation (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (2010). ICH harmonised tripartite 
guideline. Guideline for good clinical practice E6. 
http://www.ich.org/LOB/media/MEDIA482.pdf (accessed April 23, 2010). 
Johnson, L. (1994). An assessment of satisfaction of clinical research participants in a 
long term study. Int Conf AIDS. 10: 393 
Kagan, J., Kane, M., Quinlan, K., Rosas, M. & Trochim, W. (2009). Developing a 
conceptual framework for an evaluation system for the NIAID HIV/AIDS clinical 
trials networks. Health Research Policy and Systems. 7:12 doi:10.1186/1478-
4505-7-12 
Kivimäki, M., Shipley, M., Ferrie, J, Singh-Manoux, A., Batty, G., Chandola, T., 
Marmot, M. & Smith, G. (2008). Best-practice interventions to reduce 
  
125
socioeconomic inequalities of coronary heart disease mortality in UK: a 
prospective occupational cohort study. Lancet. 372(9650):1648-54. 
Lansang, M., & Dennis, R. (2004). Building capacity in health research in the developing 
world. Bulletin of the World Health Organization, 82(10), 764-770. Retrieved 
from Academic Search Complete database. 
Länsimies-Antikainen, H., Pietilä, M., Kiviniemi, V., Rauramaa, R. & Laitinen, T. 
(2009). Evaluation of Participant Comprehension of Information Received in an 
Exercise and Diet Intervention Trial: The Dr’s EXTRA Study. Gerontology. 
Doi:10.1159/000254484. 
Lazovski, J, Losso M, Krohmal B, Emanuel EJ, Grady C & Wendler D. (2009). Benefits 
and burdens of participants in a longitudinal clinical trial. Journal of Empirical 
Research on Human Research Ethics. 1556-2646.  
Le Thi Thu, H., Takano, T., Seino, K., Ohnishi, M., & Nakamura, K. (2008). 
Effectiveness of a capacity-building program for community leaders in a healthy 
living environment: a randomized community-based intervention in rural 
Vietnam. Health Promotion International, 23(4), 354-364. 
doi:10.1093/heapro/dan035. 
Lönnroth, K. & Raviglione, M. (2008). Global epidemiology of tuberculosis: prospects 
for control. Semin Respir Crit Care Med. 481-91. Epub 2008 Sep 22. Review. 
Mahomed, H., Shea, J., Kafaar, F., Hawkridge, T., Hanekorn, W., Hussey, G. (2008). Are 
adolescents ready for tuberculosis vaccine trials? Vaccine. 26:4725-4730. 
  
126
Matee, M. (2009). European and Developing Countries Clinical Trials Partnership 
(EDCTP): the path towards a true partnership. BMC Public Health. 9: 249. doi: 
10.1186/1471-2458-9-249 
Mboya-Okeyo, T., Ridley, R., & Nwaka, S. (2009). The African network for drugs and 
diagnostics innovation. Lancet, 373(9674), 1507-1508. Retrieved from Academic 
Search Complete database. 
Miller, J., Mclean, L., Coward, P. & Broemeling, A. (2009). Developing strategies to 
enhance health services in a predominantly rural canadian health authority. Rural 
and Remote Health. 9:1266. 
Ministry of Finance and Planning, Republic of Kenya (2010). Siaya District development 
plan 2002-2008. 
http://www.hungryforlife.org/site_files/0cb82d952c2562c4f2073b88770e50b2.pd
f. Retrieved on 23 March 2010.  
Minnies, D., Hawkridge, T., Hanekom, W., Ehrlich, R., Londo, L. & Hussey, G. (2008). 
Evaluation of the quality of informed consent in a vaccine field trial in a 
developing country setting. BMC Medical Ethics; 9(15):1-9. 
Mitchell, E (2009). Formative Research in TB Vaccine Development: What do we need 
to do and by when do we need to know it. Unpublished communication.  
Moodley, K., Pather, M., & Myer, L. (2005). Informed consent and participant 
perceptions of influenza vaccine trials in South Africa. Journal of Medical Ethics, 
31(12), 727-732. doi:10.1136/jme.2004.009910. 
  
127
Moran, M., Guzman, J., Ropars, A., McDonald, A., Jameson, N.& Omune, B. (2009). 
Neglected disease research and development: how much are we really spending?. 
PLoS Medicine, 6(2), e1000030. Retrieved from Academic Search Complete 
database. 
Murray, M., O'Connor, A., Stacey, D. & Wilson, K. (2008). Efficacy of a training 
intervention on the quality of practitioners' decision support for patients deciding 
about place of care at the end of life: A randomized control trial: Study protocol. 
BMC Palliat Care. 30;7:4. 
National Institute of Health (2004). Guidelines for the conduct of research involving 
human subjects at the national institute of health. U.S. Department of Health And 
Human Services.  
National Institute of Health (2008). Guidelines for the conduct of research involving 
human subjects at the national institute of health. U.S. department of health and 
human services.  
Newman, P., Duan, N., Rudy, E., & Anton, P. (2004). Challenges for HIV vaccine 
dissemination and clinical trial recruitment: if we build it, will they come? AIDS 
Patient Care & STDs, 18(12), 691-701. 
http://search.ebscohost.com.ezp.waldenulibrary.org, doi:10.1089/apc.2004.18.691 
Oduro, A., Aborigo, R., Amugsi, D.,Francis Anto, F., Anyorigiya, T. & Atuguba, F. 
(2008). Understanding and retention of the informed consent process among 
parents in rural Ghana. BMC Medical Ethics: 9:12. Doi: 10.1186/1472-6939-9-12. 
  
128
Perneger, T., Charvet-Bérard, A. & Perrier, A. (2008). Patient assessments of the most 
important medical decision during a hospitalization. J Gen Intern Med. 
23(10):1659-65.  
Rantz, M., Popejoy, L., Petroski, G., Madsen, R., Mehr, D., Zwygart-Stauffacher, M., 
Hicks, L., Grando, V., Wipke-Tevis , D., Bostick, J., Porter, R., Conn, V. & Maas, 
M.(2001). Randomized clinical trial of a quality improvement intervention in 
nursing homes. Gerontologist. 41(4):525-38. 
Reeder, J., & Taime, J. (2003). Engaging the community in research: lessons learned 
from the malaria vaccine trial. Trends in Parasitology, 19(6), 281. 
http://search.ebscohost.com.ezp.waldenulibrary.org, doi:10.1016/S1471-
4922(03)00092-8 
Robinson, J., & Trochim, W. (2007). An examination of community members', 
researchers' and health professionals' perceptions of barriers to minority 
participation in medical research: An application of concept mapping. Ethnicity & 
Health, 12(5), 521-539. doi:10.1080/13557850701616987. 
Russell, F., Carapetis, J., Liddle, H., Edwards, T., Ruff, T., & Devitt, J. (2005). A pilot 
study of the quality of informed consent materials for Aboriginal participants in 
clinical trials. 
Sack, D., Brooks, V., Behan, M., Cravioto, A., Kennedy, A., IJsselmuiden, C. & Nelson 
Sewankambo. (2009). Improving international research contracting. Bulletin of 
the World Health Organization. 487-A. Academic Search Complete, EBSCOhost 
(accessed March 21, 2010). 
  
129
Saleh, S., Williams, D., & Balougan, M. (2004). Evaluating the effectiveness of public 
health leadership training: the NEPHLI experience. American Journal of Public 
Health, 94(7), 1245-1249. Retrieved from Academic Search Complete database. 
Sandman, L., Mosher, A., Khan, A., Tapy, J., Condos, R., Ferrell, S., Vernon, A.& 
Tuberculosis Trials Consortium. (2006). Quality assurance in a large clinical trials 
consortium: the experience f the tuberculosis trials consortium. Contemporary 
Clinical Trials. 27. 554-60. 
Shi, S., Wang, B. & Wan, T. (1999). The effect of clinical information intervention on 
quality improvement in ICU patients. Association for Health Services Research 
Meeting. Abstr Book Assoc Health Serv Res Meet. 16: 373-4. 
Smith, A., Coveney, J., Carter, P., Jolley, G., & Laris, P. (2004). The Eat Well SA 
project: an evaluation-based case study in building capacity for promoting healthy 
eating. Health Promotion International, 19(3), 327-334. 
doi:10.1093/heapro/dah306 
Sobngwi, E., Mbanya, J., Unwin, N., Aspray, T, & Alberti, K. (2001). Development and 
validation of a questionnaire for the assessment of physical activity in 
epidemiological studies in Sub-Saharan Africa. Int J Epidemiol. ;30(6):1361-8. 
Stadler, J., Delany, S., & Mntambo, M. (2008). Women's perceptions and experiences of 
HIV prevention trials in Soweto, South Africa. Social Science & Medicine, 66(1), 
189-200. http://search.ebscohost.com.ezp.waldenulibrary.org, 
doi:10.1016/j.socscimed.2007.08.021Journal of Medical Ethics, 31(8), 490-494. 
doi:10.1136/jme.2002.002279 
  
130
Stanton B. (2004). Assessment of relevant cultural considerations is essential for the 
success of a vaccine. J Health Popul Nutr. ;22(3):286-92. PMID: 15609781 
Thapinta, D., Jenkins, R., Morgan, P., Chiu, J., Boenim, W & Bussaratid, V. (2002). 
Recruiting volunteers for a multisite phase i/ii hiv preventive vaccine trial in 
Thailand. Journal of Acquired Immune Deficiency Syndromes, 30(5), 503. 
http://search.ebscohost.com.ezp.waldenulibrary.org 
Tuberculosis Coalition for Technical Assistance- TCTA (2007). Guide for improving tb 
care as seen through the eyes of the patient. Amsterdam: Tuberculosis Coalition 
for Technical Assistance.  
Tumiel-Berhalter, L., Mclaughlin-Diaz, V., Vena, J. & Crespo, C. (2007). Building 
community research capacity: process evaluation of community training and 
education in a community-based participatory research program serving 
predominantly Puerto Rican community. Progr Community Health Partnersh, 
1(1), 89-87. doi:10.1353/cpr.0.0008. 
United Nations (2009). The millennium development goals 2009 report. United Nation. 
New York, NY. 
University of Puerto Rico, Medical Science Campus (2011). Audit standard of 
procedures. http://irbrcm.rcm.upr.edu/docs/auditproc.pdf. Retrieved on 04 April 
2011.  
Varshavsky S, Platonov PG.(2004). FDA inspections outside the USA: an Eastern 
European perspective. Applied Clinical trials Online. 
  
131
Volkmann, EW., Clairborne, D and Currier, J. (2009). Determinants of participation in 
HIV clinical trials: the importance of patient’s trust in their provider. HIV Clin 
Trials; 10 (2). 104-109.  
WHO (2009). Global tuberculosis control: epidemiology, strategy, financing. WHO 2009 
Report. World Health Organization (WHO/HTM/TB/2009.411) 
WHO (2006). The global plan to stop TB, 2006–2015. Geneva, World Health 
Organization, (WHO/HTM/STB/2006.35) 
WHO (2008). Joint inspection of clinical trial of conjugate meningitis A vaccine 17-19 
January 2007 in Bamako, Mali. Geneva, World Health Organization. 
 
  
132
Appendix A: Management of Data for Study 
 
Table 13 
Management of Data on Participant Satisfaction 
                               Participant Satisfaction Aspect % (N)                         
                                
Strongly 
Agree Agree Uncertain Disagree 
Strongly 
Disagree 
General Satisfaction      
The attention that I receive from the 
study staff while we interact is just 
about perfect      
I am dissatisfied with some things 
about the interactions that I have with 
study staff      
Technical Quality      
I think the study staff and their 
facilities have everything needed for 
the study      
Sometimes study staff make me 
wonder if the study is worthwhile      
When study staff examine me, they 
are careful to check that I am satisfied      
I have some doubts about the need for 
this study in the community      
Sometimes study staff use medical 
words without explaining      
Interpersonal Manners      
Study staff are too businesslike and 
impersonal toward me      
Study staff treat me in a friendly and 
courteous manner      
Study staff sometimes hurry too much 
during the study visits      
Study Staff usually spend plenty of 
time with me      
    (continued) 
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                               Participant Satisfaction Aspect % (N)                        
 
Strongly 
Agree Agree Uncertain Disagree 
Strongly 
Disagree 
Communication      
Study staff is good about 
explaining reasons for the research 
study      
Study staff sometimes ignore what 
I tell them      
Financial Aspects      
I feel confident that I can complete 
all study visits without spending 
too much money       
I have to spend more than I can 
afford to be part of this study      
Accessibility and Convenience      
The study visit hours are 
convenient for me      
I have easy access to study staff 
when I need to      
I find it hard to reach the study 
staff right away when I need to      
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Table 14 
Management of Data on Characteristics of Study Participants 
Characteristics Category % (n) 
Age < 25   
  25-35   
  > 35   
Gender Male   
  Female   
Occupation Subsistence farming    
  Fishing    
  Salaried worker (e.g. teacher, nurse, office)   
  Small business (e.g. sell maize)    
  Business owner (e.g. kiosk)    
  Skilled labor (e.g. carpenter, tailor)   
  Unskilled labor (e.g. construction)    
  Commercial farming    
  Not working   
  Other   
Level of Education None   
  Primary   
  Secondary   
  Post secondary   
Years of Education None   
  1-9   
  >9   
Duration of participation in 
the study < 6 months   
  6-12 months   
  12-18 months   
  18-24 months   
  > 24 months   
Previous personal or family 
experience with clinical 
research yes   
  no   
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Table 15 
Management of Data on Relation between Participants Characteristics and Main Satisfaction 
Aspects 
Relation Participants Characteristics and Main Satisfaction Items 
  Age group  Formal Education  Occupation  
Satisfaction Item < 25 vs. > 26 None vs. some Farming vs. other 
The attention that I receive from the 
study staff while we interact is just 
about perfect       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
I am dissatisfied with some things 
about the interactions that I have with 
study staff       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
I think the study staff and their 
facilities have everything needed for 
the study       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
Sometimes study staff make me 
wonder if the study is worthwhile       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
 
(continued)
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Relation Participants Characteristics and Main Satisfaction Items 
  Age group  Formal Education  Occupation  
Satisfaction Item < 25 vs. > 26 None vs. some Farming vs. other 
When study staff examine me, they are 
careful to check that I am satisfied       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
I have some doubts about the need for 
this study in the community       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
Sometimes study staff use medical 
words without explaining       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
Study staff are too businesslike and 
impersonal toward me       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
(continued) 
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Study staff sometimes hurry too much 
during the study visits       
% Strongly Agree       
% Agree    
% Uncertain       
% disagree       
% Strongly disagree       
Study Staff usually spend plenty of time 
with me       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
Study staff is good about explaining 
reasons for the research study       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
Study staff sometimes ignore what I tell 
them       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
(continued) 
Relation Participants Characteristics and Main Satisfaction Items 
  Age group  Formal Education  Occupation  
Satisfaction Item < 25 vs. > 26 None vs. some 
Farming vs. 
other 
Study staff treat me in a friendly and 
courteous manner       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
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Relation Participants Characteristics and Main Satisfaction Items 
  Age group  Formal Education  Occupation  
Satisfaction Item < 25 vs. > 26 None vs. some Farming vs. other 
I feel confident that I can complete all 
study visits without spending too much 
money        
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
I have to spend more than I can afford 
to be part of this study       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
The study visit hours are convenient 
for me       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
I have easy access to study staff when I 
need to       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
% Strongly disagree       
I find it hard to reach the study staff 
right away when I need to       
% Strongly Agree       
% Agree       
% Uncertain       
% disagree       
  
139
% Strongly disagree       
 
Table 16 
Management of Data on Overall Informed Consent 
Informed Consent Question 
% correct 
(n) 
 1. What was the reason you were asked to attend the clinic?    
 2. What is the purpose of the research study?   
 3. Why does the research staff want to enroll my baby into the 
research study?   
 4. What is the total amount of time my baby will be expected to 
participate in the study?   
 5. What is the most common risk involved when blood had been 
collected from my baby?   
 6. What benefits are available to me and my baby for 
participating in the study?   
 7. What if I didn't want my baby to participate in this study, I 
could withdraw    
 8. How will my baby's personal details be kept secret?   
 9. Why did I agreed to enroll my child in this study?   
 10. How long do I have to keep participating in the study?   
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Table 17 
Management of Data on Relation between Duration of Participation and Experience with 
Research and Informed Consent: % Correct Answers 
  % Correct 
  
Experience of 
staff 
administering 
consent 
Informed Consent Questions 
< 2 yrs vs. > 2 
yr 
 1. What was the reason you were 
asked to attend the clinic?    
 2. What is the purpose of the 
research study?   
 3. Why does the research staff 
want to enroll my baby into the 
research study?   
 4. What is the total amount of time 
my baby will be expected to 
participate in the study?   
 5. What is the most common risk 
involved when blood had been 
collected from my baby?   
 6. What benefits are available to 
me and my baby for participating 
in the study?   
 7. What if I didn't want my baby to 
participate in this study, I could 
withdraw    
 8. How will my baby's personal 
details be kept secret?   
 9. Why did I agree to enroll my 
child in this study?   
 10. How long do I have to keep 
participating in the study?   
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